Vorinostat (SAHA)

Name: Vorinostat (SAHA)
Brand: Selleck Chemicals
SKU: S1047
Rating: 5 (456 reviews)

For research use only.

Catalog No.S1047 Synonyms: MK0683, Suberoylanilide hydroxamic acid, Zolinza

456 publications

CAS No. 149647-78-9

Vorinostat (suberoylanilide hydroxamic acid, SAHA, MK0683, Zolinza) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.

Selleck's Vorinostat (SAHA) has been cited by 456 publications

Cell, 2020, S0092-8674(20)31394-5

PubMed: 33147445 ( click the link to review the publication )

Nat Biotechnol, 2020, 10.1038/s41587-019-0388-4

PubMed: 31959954 ( click the link to review the publication )

Cancer Cell, 2020, 13;37(4):599-617 e7

PubMed: 32243837 ( click the link to review the publication )

Cell, 2019, 176(1-2):198-212

PubMed: 30503211 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2018, 174(3):536-548.e21

PubMed: 29961578 ( click the link to review the publication )

Cell Metab, 2018, 5;27(6):1294-1308.e7

PubMed: 29754954 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Nat Med, 2015, 21(10):1163-71

PubMed: 26390243 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cell, 2014, 28;158(5):989-999.

PubMed: 25131989 ( click the link to review the publication )

Nature, 2011, 10;471(7337):235-9.

PubMed: 21390130 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

Nat Commun, 2021, 12(1):4404

PubMed: 34285225 ( click the link to review the publication )

Neuro Oncol, 2021, 23(3):376-386

PubMed: 33130903 ( click the link to review the publication )

Neuro Oncol, 2021, 23(2):226-239

PubMed: 32822486 ( click the link to review the publication )

Clin Cancer Res, 2021, clincanres.2486.2019

PubMed: 34667024 ( click the link to review the publication )

EMBO Mol Med, 2021, 13(8):e13901

PubMed: 34289240 ( click the link to review the publication )

Elife, 2021, 10e63810

PubMed: 33835029 ( click the link to review the publication )

Elife, 2021, 10e65654

PubMed: 34379055 ( click the link to review the publication )
J Colloid Interface Sci, 2021, 603:319-332

PubMed: 34186407 ( click the link to review the publication )

Oncogene, 2021, 10.1038/s41388-021-01931-1

PubMed: 34247191 ( click the link to review the publication )

EBioMedicine, 2021, 69:103457

PubMed: 34224975 ( click the link to review the publication )

Cancer Lett, 2021, 521:268-280

PubMed: 34481935 ( click the link to review the publication )

Cancer Lett, 2021, 512:28-37

PubMed: 33971281 ( click the link to review the publication )

J Pathol, 2021, 10.1002/path.5781

PubMed: 34431104 ( click the link to review the publication )

Cancers (Basel), 2021, 13(15)3862

PubMed: 34359763 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2021, 10.1111/pcmr.13014

PubMed: 34482636 ( click the link to review the publication )

Cell Death Dis, 2021, 12(6):532

PubMed: 34031358 ( click the link to review the publication )

Cells, 2021, 10(5)1001

PubMed: 33923163 ( click the link to review the publication )

Mol Cancer Ther, 2021, molcanther.MCT-21-0066-A.2021

PubMed: 34552007 ( click the link to review the publication )

Front Cell Dev Biol, 2021, 9:682561

PubMed: 34179011 ( click the link to review the publication )

Aging (Albany NY), 2021, 13(14):17978-18005

PubMed: 34253688 ( click the link to review the publication )

Pharmacol Res, 2021, 171:105787

PubMed: 34314859 ( click the link to review the publication )

Front Oncol, 2021, 11:723966

PubMed: 34604061 ( click the link to review the publication )

J Virol, 2021, JVI0085321

PubMed: 34232065 ( click the link to review the publication )

Biochem Pharmacol, 2021, 188:114546

PubMed: 33838133 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(9)4559

PubMed: 33925399 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(7)3621

PubMed: 33807238 ( click the link to review the publication )

Sci Rep, 2021, 11(1):6270

PubMed: 33737539 ( click the link to review the publication )

Ann Transl Med, 2021, 9(18):1455

PubMed: 34734007 ( click the link to review the publication )

J Enzyme Inhib Med Chem, 2021, 36(1):34-47

PubMed: 33100043 ( click the link to review the publication )

Brain Res Bull, 2021, 172:79-88

PubMed: 33895270 ( click the link to review the publication )

Genes (Basel), 2021, 12(2)260

PubMed: 33670166 ( click the link to review the publication )
Sci China Life Sci, 2021, 10.1007/s11427-020-1855-4

PubMed: 33420926 ( click the link to review the publication )

Transl Oncol, 2021, 14(10):101181

PubMed: 34298440 ( click the link to review the publication )

Transl Oncol, 2021, 14(1):100982

PubMed: 33395748 ( click the link to review the publication )

Reprod Sci, 2021, 10.1007/s43032-021-00533-2

PubMed: 33725312 ( click the link to review the publication )

Naunyn Schmiedebergs Arch Pharmacol, 2021, 10.1007/s00210-021-02140-z

PubMed: 34415354 ( click the link to review the publication )

Neurosci Lett, 2021, 764:136241

PubMed: 34509565 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00639-4

PubMed: 34731453 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2021, S0360-3016(21)02625-0

PubMed: 34348174 ( click the link to review the publication )

EBioMedicine, 2021, 65:103241

PubMed: 33647768 ( click the link to review the publication )

Exp Hematol Oncol, 2021, 10(1):19

PubMed: 33663586 ( click the link to review the publication )

Medicina (Kaunas), 2021, 57(5)456

PubMed: 34066975 ( click the link to review the publication )

J Dermatol Sci, 2021, S0923-1811(21)00005-0

PubMed: 33531202 ( click the link to review the publication )

AAPS J, 2021, 23(5):101

PubMed: 34403034 ( click the link to review the publication )

Adv Sci (Weinh), 2020, 7(21):2001364

PubMed: 33173727 ( click the link to review the publication )

Sci Adv, 2020, 6(33):eaba6617

PubMed: 32851167 ( click the link to review the publication )

Nucleic Acids Res, 2020, 10.1093/nar/gkaa088

PubMed: 32107550 ( click the link to review the publication )

EMBO Rep, 2020, 21:e50162

PubMed: 32314873 ( click the link to review the publication )

J Immunother Cancer, 2020, 8(2)e001037

PubMed: 33158915 ( click the link to review the publication )

J Immunother Cancer, 2020, 8(1)

PubMed: 31940587 ( click the link to review the publication )

Theranostics, 2020, 1;10(3):1433-1453

PubMed: 31938073 ( click the link to review the publication )

Cancer, 2020, 1;126(9):2024-2033

PubMed: 31999837 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )
Clin Epigenetics, 2020, 12(1):13

PubMed: 31941522 ( click the link to review the publication )

Br J Cancer, 2020, 27

PubMed: 32336756 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 17;8:158

PubMed: 32258036 ( click the link to review the publication )

J Neuroinflammation, 2020, 22;17(1):125

PubMed: 32321538 ( click the link to review the publication )

ACS Infect Dis, 2020, 29

PubMed: 32347704 ( click the link to review the publication )

Cancer Sci, 2020, 111(12):4429-4441

PubMed: 33043499 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Front Oncol, 2020, 10:296

PubMed: 32195191 ( click the link to review the publication )

J Virol, 2020, 4;94(10) pii: e01923-19

PubMed: 32161174 ( click the link to review the publication )

Biochem Pharmacol, 2020, 3;178:114067

PubMed: 32504550 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

HIV Med, 2020, 21(11):747-757

PubMed: 33369029 ( click the link to review the publication )

Am J Transl Res, 2020, 12(10):6187-6203

PubMed: 33194023 ( click the link to review the publication )

Andrology, 2020, 10.1111/andr.12922

PubMed: 33064925 ( click the link to review the publication )

BMC Microbiol, 2020, 20(1):28

PubMed: 32028887 ( click the link to review the publication )

PLoS One, 2020, 15;15(5):e0232985

PubMed: 32413049 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

J Med Invest, 2020, 67(3.4):343-350

PubMed: 33148913 ( click the link to review the publication )

Sci Rep, 2020, 10(1):12864

PubMed: 32733053 ( click the link to review the publication )

Oncol Lett, 2020, 19(1):460-468

PubMed: 31897159 ( click the link to review the publication )

Sci Adv, 2020, 6(29):eaba1941

PubMed: 32832623 ( click the link to review the publication )

Colloids Surf B Biointerfaces, 2020, 188:110753

PubMed: 31884084 ( click the link to review the publication )

Acta Pharm Sin B, 2020, 10(4):615-627

PubMed: 32322466 ( click the link to review the publication )
Cancer Sci, 2020, 111(7):2374-2384

PubMed: 32391602 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01394-w

PubMed: 32709923 ( click the link to review the publication )

Viruses, 2020, 12(10)E1067

PubMed: 32977702 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01408-7

PubMed: 32733069 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-01191-y

PubMed: 33250513 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(2):637-649

PubMed: 31784455 ( click the link to review the publication )

Genes Dev, 2020, 34(5-6):428-445

PubMed: 32001510 ( click the link to review the publication )

Cancer Manag Res, 2020, 12:4429-4439

PubMed: 32606937 ( click the link to review the publication )

Biomater Sci, 2020, 10.1039/d0bm00119h

PubMed: 32706009 ( click the link to review the publication )

Cell Cycle, 2020, 1-16

PubMed: 32807015 ( click the link to review the publication )

Life Sci, 2020, 248:117469

PubMed: 32109485 ( click the link to review the publication )

Chin Med J (Engl), 2020, 5;133(11):1304-1311

PubMed: 32452893 ( click the link to review the publication )

Pharmaceuticals (Basel), 2020, 13(11)E345

PubMed: 33121173 ( click the link to review the publication )

Pharm Biol, 2020, 58(1):231-238

PubMed: 32202448 ( click the link to review the publication )

PLoS Biol, 2020, 18(12):e3000941

PubMed: 33264286 ( click the link to review the publication )

PLoS Biol, 2020, 18(11):e3000981

PubMed: 33253182 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4192

PubMed: 31519896 ( click the link to review the publication )

J Pineal Res, 2019, 66(3):e12556

PubMed: 30648757 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

Theranostics, 2019, 9(2):540-553

PubMed: 30809292 ( click the link to review the publication )

Cancer Res, 2019, 79(7):1658-1670

PubMed: 30737231 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30652970 ( click the link to review the publication )
Int J Cancer, 2019, 145(9):2496-2508

PubMed: 30963560 ( click the link to review the publication )

Mol Ther, 2019, 27(5):1039-1050

PubMed: 30852137 ( click the link to review the publication )

Cancers (Basel), 2019, 11(5)E645

PubMed: 31083396 ( click the link to review the publication )

Cancers (Basel), 2019, 11(4)

PubMed: 30935067 ( click the link to review the publication )

Clin Epigenetics, 2019, 11(1):85

PubMed: 31142371 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(5):937-951

PubMed: 31649844 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Cancer Discov, 2019, 9(4):526-545

PubMed: 30709805 ( click the link to review the publication )

Front Immunol, 2019, 9:3162

PubMed: 30723480 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Cell Commun Signal, 2019, 17(1):4

PubMed: 30642362 ( click the link to review the publication )

Oncologist, 2019, 24(8):e740-e748

PubMed: 30696721 ( click the link to review the publication )

Mol Oncol, 2019, 10.1002/1878-0261.12607

PubMed: 31782885 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656155

PubMed: 31423895 ( click the link to review the publication )

Epigenetics, 2019, 14(8):791-803

PubMed: 31088315 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656156

PubMed: 31423932 ( click the link to review the publication )

AIDS, 2019, 33(2):199-209

PubMed: 30562171 ( click the link to review the publication )

Hum Mol Genet, 2019, 10.1093/hmg/ddz254

PubMed: 31691806 ( click the link to review the publication )

Pharmacol Res, 2019, 139:524-534

PubMed: 30366100 ( click the link to review the publication )

Pharmacol Res, 2019, 146:104281

PubMed: 31125601 ( click the link to review the publication )

J Neurochem, 2019, 10.1111/jnc.14935

PubMed: 31811660 ( click the link to review the publication )

Mol Pharm, 2019, 16(9):3904-3915

PubMed: 31318566 ( click the link to review the publication )

Bone, 2019, 125:112-121

PubMed: 31100533 ( click the link to review the publication )

Front Cell Neurosci, 2019, 13:468

PubMed: 31708743 ( click the link to review the publication )
Int J Mol Sci, 2019, 20(13)

PubMed: 31269745 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Apoptosis, 2019, 24(5-6):404-413

PubMed: 30997620 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4437-4449

PubMed: 30670592 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(5):677-688

PubMed: 30224636 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2019, 22(8):523-527

PubMed: 31179497 ( click the link to review the publication )

NMR Biomed, 2019, 32(2):e4044

PubMed: 30561869 ( click the link to review the publication )

Cancer Biol Ther, 2019,

PubMed: 30142009 ( click the link to review the publication )

Stem Cells Dev, 2019, 28(7):438-453

PubMed: 30667343 ( click the link to review the publication )

Chem Biol Interact, 2019, 306:54-61

PubMed: 30958996 ( click the link to review the publication )

Gene Ther, 2019, 26(3-4):75-85

PubMed: 30538307 ( click the link to review the publication )

Cancer Med, 2019, 8(14):6383-6392

PubMed: 31456359 ( click the link to review the publication )

Tuberculosis (Edinb), 2019, 118:101861

PubMed: 31526947 ( click the link to review the publication )

PLoS One, 2019, 14(6):e0218382

PubMed: 31206526 ( click the link to review the publication )

ACS Omega, 2019, 4(22):19895-19904

PubMed: 31788622 ( click the link to review the publication )

Exp Hematol, 2019, 72:60-71

PubMed: 30769020 ( click the link to review the publication )

Nucl Med Biol, 2019, 74-75:1-11

PubMed: 31421440 ( click the link to review the publication )

Alcohol, 2019, 78:79-87

PubMed: 30851364 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3579-3584

PubMed: 31262882 ( click the link to review the publication )

Neoplasma, 2019, 66(1):20-27

PubMed: 30509083 ( click the link to review the publication )

Res Vet Sci, 2019, 126:207-212

PubMed: 31610471 ( click the link to review the publication )

Exp Ther Med, 2019, 17(6):4547-4553

PubMed: 31186678 ( click the link to review the publication )

Thyroid, 2019, 29(5):726-734

PubMed: 30760120 ( click the link to review the publication )

Medicina (Kaunas), 2019, 55(2)

PubMed: 30700046 ( click the link to review the publication )
Adipocyte, 2019, 8(1):292-303

PubMed: 31322450 ( click the link to review the publication )

Oncol Rep, 2019, 41(2):1007-1018

PubMed: 30431129 ( click the link to review the publication )

Chin J Dent Res, 2019, 22(4):221-227

PubMed: 31859282 ( click the link to review the publication )

Front Neurol, 2019, 10:893

PubMed: 31481925 ( click the link to review the publication )

Cell Host Microbe, 2018, 24(5):689-702

PubMed: 30344003 ( click the link to review the publication )

Nat Commun, 2018, 13;9(1):2720

PubMed: 30006524 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3941-3954

PubMed: 29764852 ( click the link to review the publication )

Cancer Res, 2018, 78(10):2705-2720

PubMed: 29490948 ( click the link to review the publication )

Cancer Res, 2018, 78(20):5731-5740

PubMed: 30135193 ( click the link to review the publication )

J Control Release, 2018, 275:117-128

PubMed: 29474960 ( click the link to review the publication )

Haematologica, 2018, 103(4):679-687

PubMed: 29305415 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):32

PubMed: 29486795 ( click the link to review the publication )

Cancer Lett, 2018, 432:121-131

PubMed: 29890207 ( click the link to review the publication )

Acta Biomater, 2018, 71:261-270

PubMed: 29526828 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459282 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):153

PubMed: 30012171 ( click the link to review the publication )

PLoS Pathog, 2018, 14(6):e1007061

PubMed: 29879225 ( click the link to review the publication )

Oncoimmunology, 2018,

PubMed: 30377559 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2767-2779

PubMed: 30232145 ( click the link to review the publication )

Cancer Sci, 2018, 109(8):2520-2531

PubMed: 29917299 ( click the link to review the publication )

J Virol, 2018, 92(10)

PubMed: 29343578 ( click the link to review the publication )

J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )

J Cell Mol Med, 2018, 22(5):2600-2611

PubMed: 29461008 ( click the link to review the publication )

Front Pharmacol, 2018, 9:509

PubMed: 29867508 ( click the link to review the publication )
Sci Rep, 2018, 8(1):3875

PubMed: 29497113 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3521

PubMed: 29476067 ( click the link to review the publication )

Front Microbiol, 2018, 9:2022

PubMed: 30283406 ( click the link to review the publication )

J Cell Biochem, 2018, 119(5):4193-4204

PubMed: 29274289 ( click the link to review the publication )

Retrovirology, 2018, 15(1):36

PubMed: 29751762 ( click the link to review the publication )

Exp Cell Res, 2018, 371(1):231-237

PubMed: 30107147 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):466

PubMed: 29695239 ( click the link to review the publication )

Biol Sex Differ, 2018, 9(1):12

PubMed: 29530094 ( click the link to review the publication )

Oncol Rep, 2018, 39(1):264-270

PubMed: 29115632 ( click the link to review the publication )

Ann Hematol, 2018, 97(5):839-849

PubMed: 29359239 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 498(3):481-486

PubMed: 29505792 ( click the link to review the publication )

AAPS PharmSciTech, 2018, 19(2):634-647

PubMed: 28948528 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(8):398-407

PubMed: 30484863 ( click the link to review the publication )

J Med Virol, 2018, 90(9):1478-1485

PubMed: 29704439 ( click the link to review the publication )

Curr Protoc Pharmacol, 2018, 81(1):e41

PubMed: 29927058 ( click the link to review the publication )

Alcohol Clin Exp Res, 2018, 42(11):2160-2171

PubMed: 30103280 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):6107-6114

PubMed: 29731842 ( click the link to review the publication )

JCI Insight, 2018, 3(4)95824

PubMed: 29467324 ( click the link to review the publication )

Sci Adv, 2018, 4(9):eaar4666

PubMed: 30263952 ( click the link to review the publication )

JCI Insight, 2018, 3(22)125568

PubMed: 30429379 ( click the link to review the publication )

Nat Struct Mol Biol, 2017, 24(1):47-54

PubMed: 27870832 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3139-3149

PubMed: 27986747 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2017,

PubMed: 28673995 ( click the link to review the publication )

Haematologica, 2017, 102(4):736-745

PubMed: 27979926 ( click the link to review the publication )
Clin Cancer Res, 2017, 23(12):3084-3096

PubMed: 27993968 ( click the link to review the publication )

Oncogene, 2017, 36(34):4859-4874

PubMed: 28414307 ( click the link to review the publication )

Oncogene, 2017, 36(12):1707-1720

PubMed: 27694895 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(20):3608-3622

PubMed: 28749535 ( click the link to review the publication )

Sci Signal, 2017, 10(508)eaan8355

PubMed: 29208683 ( click the link to review the publication )

Cell Death Dis, 2017, 8(1):e2570

PubMed: 28125090 ( click the link to review the publication )

Cell Death Dis, 2017,

PubMed: 29022919 ( click the link to review the publication )

Mol Ther Oncolytics, 2017,

PubMed: 28812060 ( click the link to review the publication )

Cell Chem Biol, 2017, 24(11):1356-1367.e8

PubMed: 28943357 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Eur J Med Chem, 2017, 127:531-553

PubMed: 28109947 ( click the link to review the publication )

Eur J Med Chem, 2017, 141:596-602

PubMed: 29102179 ( click the link to review the publication )

Cancer Sci, 2017, 108(7):1485-1492

PubMed: 28498513 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(5)

PubMed: 28481295 ( click the link to review the publication )

Sci Rep, 2017, 7(1):11547

PubMed: 28912522 ( click the link to review the publication )

Sci Rep, 2017, 7(1):10921

PubMed: 28883618 ( click the link to review the publication )

J Biol Chem, 2017, 292(12):5043-5054

PubMed: 28167529 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(2):211-220

PubMed: 28860353 ( click the link to review the publication )

Pharm Res, 2017, 34(3):668-679

PubMed: 28101809 ( click the link to review the publication )

Cancer Res Treat, 2017, 49(2):374-386

PubMed: 27488871 ( click the link to review the publication )

Cancer Med, 2017, 6(11):2673-2685

PubMed: 29024573 ( click the link to review the publication )

Mol Immunol, 2017, 87:76-85

PubMed: 28412547 ( click the link to review the publication )

Int J Cell Biol, 2017, 2017:6169310

PubMed: 28321257 ( click the link to review the publication )

PLoS One, 2017, 12(10):e0186620

PubMed: 29045501 ( click the link to review the publication )
Connect Tissue Res, 2017, 58(1):64-75

PubMed: 27404795 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:88-95

PubMed: 28323055 ( click the link to review the publication )

Am J Surg, 2017, 213(4):645-651

PubMed: 28007318 ( click the link to review the publication )

Nucleus, 2017, 8(5):515-533

PubMed: 28696859 ( click the link to review the publication )

Oncotarget, 2017, 8(11):17995-18009

PubMed: 28152508 ( click the link to review the publication )

Oncotarget, 2017, 8(28):45687-45697

PubMed: 28537899 ( click the link to review the publication )

Oncotarget, 2017, 9(1):512-523

PubMed: 29416632 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51429-51446

PubMed: 28881658 ( click the link to review the publication )

CPT Pharmacometrics Syst Pharmacol, 2017, 6(11):756-764

PubMed: 29045072 ( click the link to review the publication )

Sci Rep, 2017, 7(1):2290

PubMed: 28536458 ( click the link to review the publication )

Oncotarget, 2017, 8(45):78480-78495

PubMed: 29108243 ( click the link to review the publication )

Oncotarget, 2017, 8(61):103797-103814

PubMed: 29262601 ( click the link to review the publication )

JCI Insight, 2017, 2(1):e85811

PubMed: 28097226 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28423644 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Bioorg Med Chem, 2017, 25(7):2105-2132

PubMed: 28259528 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29371976 ( click the link to review the publication )

Oncotarget, 2017, 10.18632/oncotarget.15017

PubMed: 28157715 ( click the link to review the publication )

Oncotarget, 2017, 8(44):77254-77267

PubMed: 29100385 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(5):569-579

PubMed: 28494238 ( click the link to review the publication )

Ann Oncol, 2016, 27(3):508-13

PubMed: 26658891 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Cancer Res, 2016, 76(23):7001-7011

PubMed: 27671680 ( click the link to review the publication )

Cancer Res, 2016, 76(8):2376-83

PubMed: 26941288 ( click the link to review the publication )
Cell Death Differ, 2016, 23(8):1312-21

PubMed: 26915294 ( click the link to review the publication )

Int J Cancer, 2016, 139(1):194-204

PubMed: 26914605 ( click the link to review the publication )

Drug Discov Today, 2016, 21(9):1553-1560

PubMed: 27371506 ( click the link to review the publication )

mBio, 2016, 7(6)

PubMed: 27803184 ( click the link to review the publication )

J Med Chem, 2016, 59(4):1613-33

PubMed: 26681404 ( click the link to review the publication )

Oncoimmunology, 2016,

PubMed: 27471639 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2432-2441

PubMed: 27474150 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(6):1364-75

PubMed: 27196750 ( click the link to review the publication )

Endocr Relat Cancer, 2016, 23(7):521-33

PubMed: 27267120 ( click the link to review the publication )

Mol Cell Proteomics, 2016, 15(6):2076-92

PubMed: 27067055 ( click the link to review the publication )

ACS Chem Biol, 2016, 11(10):2685-2692

PubMed: 27459069 ( click the link to review the publication )

Neuropharmacology, 2016, 107:111-121

PubMed: 26970016 ( click the link to review the publication )

Biochem Pharmacol, 2016, 102:130-140

PubMed: 26718586 ( click the link to review the publication )

Sci Rep, 2016, 6:38219

PubMed: 27910887 ( click the link to review the publication )

Am J Pathol, 2016, 186(10):2701-8

PubMed: 27555113 ( click the link to review the publication )

J Biol Chem, 2016, 291(19):10131-47

PubMed: 27022024 ( click the link to review the publication )

Neurochem Int, 2016, 96:24-31

PubMed: 27103167 ( click the link to review the publication )

Int J Oncol, 2016, 49(6):2453-2463

PubMed: 27748897 ( click the link to review the publication )

Am J Physiol Heart Circ Physiol, 2016, 311(5):H1139-H1149

PubMed: 27638876 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(1):27-35

PubMed: 26575826 ( click the link to review the publication )

Anal Bioanal Chem, 2016, 408(13):3547-53

PubMed: 26968571 ( click the link to review the publication )

BMC Cancer, 2016, 16:667

PubMed: 27549189 ( click the link to review the publication )

Biol Chem, 2016,

PubMed: 26431101 ( click the link to review the publication )

J Hum Genet, 2016, 10.1038/jhg.2016.61

PubMed: 27251006 ( click the link to review the publication )
Med Oncol, 2016, 33(2):11

PubMed: 26732474 ( click the link to review the publication )

Inflammation, 2016, 39(1):39-46

PubMed: 26228975 ( click the link to review the publication )

PLoS One, 2016, 11(8):e0160826

PubMed: 27536989 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0145985

PubMed: 26726879 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:6843-6855

PubMed: 27877053 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(3):692-9

PubMed: 26084206 ( click the link to review the publication )

Asian Pac J Trop Med, 2016, 9(6):572-6

PubMed: 27262069 ( click the link to review the publication )

Oncotarget, 2016, 7(42):68360-68370

PubMed: 27588392 ( click the link to review the publication )

Genet Mol Res, 2016, 15(4)

PubMed: 27819724 ( click the link to review the publication )

Oncotarget, 2016, 8(62):104733-104744

PubMed: 29285209 ( click the link to review the publication )

Oncotarget, 2016, 7(7):7390-402

PubMed: 26862729 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 26824319 ( click the link to review the publication )

Oncotarget, 2016, 7(36):58142-58147

PubMed: 27494885 ( click the link to review the publication )

Sci Rep, 2016, 6:21678

PubMed: 26902929 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6727-47

PubMed: 26734995 ( click the link to review the publication )

Nat Commun, 2015, 6:7888

PubMed: 26223951 ( click the link to review the publication )

Nat Commun, 2015, 3;6:10091

PubMed: 26631872 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404580

PubMed: 25759362 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2701

PubMed: 25813020 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(7):1628-38

PubMed: 25623213 ( click the link to review the publication )

Cancer Res, 2015,

PubMed: 26294211 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

Cell Death Differ, 2015, 22(8):1328-40

PubMed: 25591738 ( click the link to review the publication )
Int J Cancer, 2015, 136(11):2717-29

PubMed: ( click the link to review the publication )

EBioMedicine, 2015, 3:108-121

PubMed: 26870822 ( click the link to review the publication )

Cancer Lett, 2015, 356(2 Pt B):828-36

PubMed: 25449774 ( click the link to review the publication )

Cancer Lett, 2015, 366(1):32-43

PubMed: 26028172 ( click the link to review the publication )

Breast Cancer Res, 2015, 17:33

PubMed: 25888415 ( click the link to review the publication )

J Neurosci, 2015, 35(33):11729-42

PubMed: 26290249 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1692

PubMed: 25766331 ( click the link to review the publication )

Cell Death Discov, 2015, 115012

PubMed: 26279947 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1657

PubMed: 25695609 ( click the link to review the publication )

Acta Neuropathol Commun, 2015, 3(1):22

PubMed: 25853389 ( click the link to review the publication )

Endocr Relat Cancer, 2015, 22(5):777-92

PubMed: 26206775 ( click the link to review the publication )

Br J Haematol, 2015, 168(3):371-83

PubMed: 25284154 ( click the link to review the publication )

Br J Haematol, 2015, 168(3):371-83

PubMed: ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(4):1337-52

PubMed: 26101701 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(10):2316-24

PubMed: 26162280 ( click the link to review the publication )

Neuropharmacology, 2015, 99:67-78

PubMed: 26188143 ( click the link to review the publication )

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed: ( click the link to review the publication )

Biochem Pharmacol, 2015, 94(2):79-90

PubMed: 25600908 ( click the link to review the publication )

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed: ( click the link to review the publication )

Apoptosis, 2015, 20(7):975-85

PubMed: 25835755 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: 25540204 ( click the link to review the publication )

J Biol Chem, 2015, 290(39):23725-37

PubMed: 26269591 ( click the link to review the publication )

J Biol Chem, 2015, 290(3):1829-36

PubMed: 25492871 ( click the link to review the publication )
J Biol Chem, 2015, 290(8):5028-40

PubMed: ( click the link to review the publication )

Front Mol Neurosci, 2015, 8:52

PubMed: 26441515 ( click the link to review the publication )

BMC Cancer, 2015, 15:343

PubMed: 25929737 ( click the link to review the publication )

BMC Cancer, 2015, 15(1):273

PubMed: 25880212 ( click the link to review the publication )

FEBS Lett, 2015, 589(10):1080-8

PubMed: 25816750 ( click the link to review the publication )

PLoS One, 2015, 10(6):e0130339

PubMed: 26091518 ( click the link to review the publication )

PLoS One, 2015, 10(10):e0139740

PubMed: 26466379 ( click the link to review the publication )

PLoS One, 2015, 10(8):e0134825

PubMed: 26284517 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0143897

PubMed: 26623653 ( click the link to review the publication )

J Biotechnol, 2015, 10.1016/j.jbiotec.2015.02.029

PubMed: 25746901 ( click the link to review the publication )

J Biomol Screen, 2015, 20(10):1286-93

PubMed: 26384394 ( click the link to review the publication )

Mol Vis, 2015, 21:502-14

PubMed: 25999677 ( click the link to review the publication )

Mol Med Rep, 2015, 12(3):4291-4297

PubMed: 26095064 ( click the link to review the publication )

Genes Cancer, 2015, 6(3-4):169-81

PubMed: 26000099 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25801-14

PubMed: 26317649 ( click the link to review the publication )

Circ Heart Fail, 2015, 8(6):1094-104

PubMed: 26371176 ( click the link to review the publication )

Sci Transl Med, 2014, 6(256):256ra135

PubMed: 25273096 ( click the link to review the publication )

Acta Neuropathol, 2014, 128(2):291-303

PubMed: 24839957 ( click the link to review the publication )

Nat Commun, 2014, 5:3361

PubMed: 24553445 ( click the link to review the publication )

Clin Cancer Res, 2014, 10.1158/1078-0432.CCR-14-0384

PubMed: 25355930 ( click the link to review the publication )

Int J Cancer, 2014, 135(7):1721-32

PubMed: 24615207 ( click the link to review the publication )

Diabetes, 2014, 63(9):2924-34

PubMed: 24722245 ( click the link to review the publication )

Oncogene, 2014, 33(25):3307-15

PubMed: 23995789 ( click the link to review the publication )
Cancer Lett, 2014, 10.1016/j.canlet.2014.10.034

PubMed: ( click the link to review the publication )

Cancer Lett, 2014, 351(1):50-8

PubMed: 24814395 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1177

PubMed: 24743732 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(12):2784-92

PubMed: 25319394 ( click the link to review the publication )

J Mol Biol, 2014, 426(20):3442-53

PubMed: 24657767 ( click the link to review the publication )

Hum Gene Ther, 2014, 25(7):599-608

PubMed: 24568341 ( click the link to review the publication )

J Biol Chem, 2014, 289(14):9918-25

PubMed: 24515107 ( click the link to review the publication )

Cancer Cell Int, 2014, 10.1186/s12935-014-0112-x

PubMed: ( click the link to review the publication )

Cancer Cell Int, 2014, 14(1):112

PubMed: 25546354 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(7):1280-9

PubMed: 24469401 ( click the link to review the publication )

Proteomics Clin Appl, 2014, 8(11-12):924-31

PubMed: 25091122 ( click the link to review the publication )

J Alzheimers Dis, 2014, 41(4):1193-205

PubMed: 24844691 ( click the link to review the publication )

Virology, 2014, 462-463:328-39

PubMed: 25014309 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(5):578-85

PubMed: 24556916 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(3):305-16

PubMed: 24351423 ( click the link to review the publication )

BMC Cancer, 2014, 14(1):373

PubMed: 24886166 ( click the link to review the publication )

FEBS Lett, 2014, 588(9):1571-9

PubMed: 24607544 ( click the link to review the publication )

PLoS One, 2014, 9(11):e113341

PubMed: 25409334 ( click the link to review the publication )

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623 ( click the link to review the publication )

Oncol Lett, 2014, 7(5):1673-1678

PubMed: 24765199 ( click the link to review the publication )

Oncotarget, 2014, 5(14):5637-50

PubMed: 25026298 ( click the link to review the publication )

Pharmacol Res Perspect, 2014, 2(3):e00043

PubMed: 25505589 ( click the link to review the publication )
Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420 ( click the link to review the publication )

Cytometry A, 2014, 85(1):78-87

PubMed: 24038859 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Pharmacology Research Perspectives, 2014, 10.1002/prp2.43

PubMed: ( click the link to review the publication )

Methods Mol Biol, 2014, 1156:431-43

PubMed: 24792006 ( click the link to review the publication )

Oncotarget, 2014, 5(15):5965-77

PubMed: 25115389 ( click the link to review the publication )

Blood, 2013, 14;121(11):2038-50

PubMed: 23327920 ( click the link to review the publication )

Blood, 2013, 123(5):706-16

PubMed: 24319254 ( click the link to review the publication )

Nat Struct Mol Biol, 2013, 20(3):317-25

PubMed: 23377543 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 111(3):E364-73

PubMed: 24395801 ( click the link to review the publication )

PLoS Biol, 2013, 12(1):e1001758

PubMed: 24409098 ( click the link to review the publication )

Cancer Res, 2013, 73(8):2428-34

PubMed: 23382048 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Int J Cancer, 2013, 132(9):2200-8

PubMed: 23024001 ( click the link to review the publication )

Neuropsychopharmacology, 2013, 38(9):1674-84

PubMed: 23474591 ( click the link to review the publication )

Oncogene, 2013, 33(33):4265-72

PubMed: 24292675 ( click the link to review the publication )

Oncogene, 2013, 32(10):1316-29

PubMed: 22543582 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e733

PubMed: 23868066 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Br J Haematol, 2013, 160(2):188-98

PubMed: 23167276 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

Apoptosis, 2013, 18(11):1348-1362

PubMed: 23708756 ( click the link to review the publication )

J Biol Chem, 2013, 288(35):25593-602

PubMed: 23878197 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14400-7

PubMed: 23539624 ( click the link to review the publication )
PLoS Comput Biol, 2013, 9(2):e1002887

PubMed: 23408876 ( click the link to review the publication )

Mol Carcinog, 2013, 52(3):218-28

PubMed: 22121107 ( click the link to review the publication )

Front Pharmacol, 2013, 4:44

PubMed: 23596417 ( click the link to review the publication )

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462 ( click the link to review the publication )

Cell Cycle, 2013, 12(13):2073-83

PubMed: 23759592 ( click the link to review the publication )

PLoS One, 2013, 8(6):e66130

PubMed: 23762475 ( click the link to review the publication )

PLoS One, 2013, 8(1):e53766

PubMed: 23320102 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e655

PubMed: 23744355 ( click the link to review the publication )

Blood, 2012, 8;120(19):3958-67

PubMed: 22983447 ( click the link to review the publication )

J Exp Med, 2012, 209(1):35-50

PubMed: 22231305 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(14):3822-33

PubMed: 22623731 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(2):408-16

PubMed: 22038994 ( click the link to review the publication )

Cancer Res, 2012, 72(9):2251-61

PubMed: 22422937 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):2029-39

PubMed: 22858545 ( click the link to review the publication )

Cell Death Differ, 2012, 19(8):1317-27

PubMed: 22322857 ( click the link to review the publication )

Eur J Cancer, 2012, 48(7):1096-107

PubMed: 22154545 ( click the link to review the publication )

Diabetologia, 2012, 55(9):2421-31

PubMed: 22772764 ( click the link to review the publication )

FASEB J, 2012, 26(7):3032-41

PubMed: 22459148 ( click the link to review the publication )

J Neurochem, 2012, 123 Suppl 2:108-15

PubMed: 23050648 ( click the link to review the publication )

J Leukoc Biol, 2012, 91(5):701-9

PubMed: 22028329 ( click the link to review the publication )

J Biol Chem, 2012, 287(43):36609

PubMed: 22952229 ( click the link to review the publication )

Mol Carcinog, 2012, 52(6):459-74

PubMed: 22308110 ( click the link to review the publication )

Invest New Drugs, 2012, 30(2):541-7

PubMed: 21107885 ( click the link to review the publication )
Pharm Res, 2012, 29(7):1960-76

PubMed: 22415140 ( click the link to review the publication )

Oncol Rep, 2012, 28(1):105-10

PubMed: 22484732 ( click the link to review the publication )

PLoS One, 2012, 7(7):e40684

PubMed: 22808232 ( click the link to review the publication )

PLoS One, 2012, 7(9):e44265

PubMed: 22957056 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52335

PubMed: 23272238 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52753

PubMed: 23300762 ( click the link to review the publication )

Biochem Biophys Res Commun, 2012, 420(2):325-30

PubMed: 22425986 ( click the link to review the publication )

Chronobiol Int, 2012, 29(8):982-93

PubMed: 22891617 ( click the link to review the publication )

Pediatr Surg Int, 2012, 28(6):579-89

PubMed: 22526548 ( click the link to review the publication )

Protein Expr Purif, 2012, 86(1):45-52

PubMed: 21992606 ( click the link to review the publication )

Brain, 2011, 134(Pt 8):2408-21

PubMed: 21772061 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(9):2819-29

PubMed: 21357681 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(16):5311-21

PubMed: 21724551 ( click the link to review the publication )

Genes Dev, 2011, 25(24):2610-8

PubMed: 22016339 ( click the link to review the publication )

J Neurosci, 2011, 31(11):3990-9

PubMed: 21411642 ( click the link to review the publication )

J Transl Med, 2011, 9:37

PubMed: 21477288 ( click the link to review the publication )

Retrovirology, 2011, 2(3):411-23

PubMed: 21966324 ( click the link to review the publication )

Mol Med, 2011, 17(5-6):466-72

PubMed: 21424110 ( click the link to review the publication )

PLoS One, 2011, 6(6):e21382

PubMed: 21738649 ( click the link to review the publication )

PLoS One, 2011, 6(7):e22739

PubMed: 21818379 ( click the link to review the publication )

BMC Neurosci, 2011, 12:50

PubMed: 21615950 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

J Pharmacol Exp Ther, 2010, 86(16):8765-72

PubMed: 20739454 ( click the link to review the publication )

Exp Dermatol, 2010, 19(12):1096-102

PubMed: 20629733 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Vorinostat (suberoylanilide hydroxamic acid, SAHA, MK0683, Zolinza) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.

Targets

HDAC ^[1]
(Cell-free assay)

~10 nM

In vitro

Vorinostat inhibits the activities of HDAC1 and HDAC3 with IC50 of 10 nM and 20 nM, respectively. Vorinostat also results in a marked hyperacetylation of histone H4. ^[1] Vorinostat inhibits the growth of three prostate cancer cell lines LNCaP, PC-3 and TSU-Pr1 at micromolar concentrations (2.5-7.5 μM), and induces dose-dependent cell death in LNCaP cells. ^[2] Vorinostat treatment in MCF-7 cells inhibits cell proliferation at an IC50 of 0.75 μM resulting in the accumulation of cells in the G1 and G2-M phase of the cell cycle. Vorinostat also induces differentiation in the estrogen receptor-negative cell line SKBr-3 and the retinoblastoma-negative cell line MDA-468. ^[3] Vorinostat treatment at 1 μM for 8 hours or more is sufficient to irreversibly induce apoptosis of human multiple myeloma (MM) cells. The gene expression profiles of Vorinostat treated MM cells are not hallmarked by global transcriptional activation, but by coordinated transcriptional changes of specific functional groups of genes such as cytokine-induced proliferative/survival signaling cascades, oncogenes-tumor suppressor genes, regulators of apoptosis, DNA synthesis-repair and cell cycle, and proteasome-ubiquitin function. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
H1299	MV7LbY5ie2ViQYPzZZk>		MUCyNEBucW5?	MY\EUXNQ	M1fOemlvcGmkaYTvdpkh[WO2aY\peJkh[WejaX7zeEBJTEGFIHXufplu\SC5aYToJGlEPTBib3[gNE4yQTRizszN	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPDV{MUSyNkc,OTR3MkG0NlI9N2F-
HT1080	M3r5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1Hv[\|czKGh?	MUnEUXNQ	NVPteZpyUUN3ME2yMlQh\|ryP	NITHdnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkK3NFE4PSd-MUKyO\|AyPzV:L3G+
K562	MU\LbY5ie2ViQYPzZZk>		MVS2JIg>	NHzuUHVFVVOR	MWXJcohq[mm2aX;uJI9nKGi3bXHuJIhqe3SxbnWg[IVi[2W2eXzhd4UhMG2reIT1doUhd2ZiSFTBR\|Eh[W6mIFjERWMzMSC5aYToJGlEPTBib3[gNE4xOSEQvF2=	NHu0fGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkSxPVM5OCd-MUK0NVk{QDB:L3G+
A20	MYHLbY5ie2ViQYPzZZk>		M2LUeVEhcA>?	MmDOSG1UVw>?	MnTYZY51cS2KRFHDNUBi[3Srdnn0fUB4cXSqIFnDOVAhd2ZiMD6xNVIh\|ryP	NIr3VpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUm2NFQ5QSd-MUG5OlA1QDl:L3G+
Friend leukemic cell	NWrUZ3N{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUe1NEDPxE1?	M2DRNVczKGh?	MoHzSG1UVw>?	MYfJR\|UxRTBwOUmg{txO	MnTJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzMEm5NVMoRjF{MUC5PVE{RC:jPh?=
H1299	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2LJ[\|czKGh?	MkHYSG1UVw>?	NFXqTW1KSzVyPUeuNlQh\|ryP	MoTGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTR3MkG0NlIoRjF2NUKxOFIzRC:jPh?=
HeLa	NUTBXXo6U2mwYYPlJGF{e2G7		NVHZdnFTOzBibXnu		NET2enFKdmirYnn0c5J6KGOxbnPlcpRz[XSrb36gZYdicW6\|dDDobZN1d26nIHTlZYNmfHmuYYPlJJdqfGhiSVO1NEBw\iByLkK4JO69VQ>?	MnK5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV4MEO5OFkoRjF3NkCzPVQ6RC:jPh?=
LOX-IMVI	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVW0PEBp		M1;oR2lEPTB;MT6zJO69VQ>?	NGPOZ5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUexOVQ4OCd-MUW3NVU1PzB:L3G+
NCI-H226	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVi0PEBp		MXzJR\|UxRTJwNjFOwG0>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTdzNUS3NEc,OTV5MUW0O\|A9N2F-
RXF-631L	MnvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3O1RVQ5KGh?		MnTNTWM2OD1{IN88US=>	M2O5ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3N{G1OFcxLz5zNUexOVQ4ODxxYU6=
SNB-78	M1[1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3:5SlQ5KGh?		NIexd4xKSzVyPUG2JO69VQ>?	NILRVIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUexOVQ4OCd-MUW3NVU1PzB:L3G+
St-4	NWXxVY5rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M17xb\|Q5KGh?		NHHWUIRKSzVyPUWuNkDPxE1?	M1XpUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3N{G1OFcxLz5zNUexOVQ4ODxxYU6=
ARP1	NX;0e3BsTnWwY4Tpc44hSXO\|YYm=	NVK3U3dXOiEQvF2=	MWW2JIg>		NVzNSnFoUW6mdXP0bY9vKG:oIGCyNXdCTjFiZ3Xu[UBmgHC{ZYPzbY9v	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPDd\|NEiwOkc,OTR5M{S4NFY9N2F-
CEM	NVnWbo1CU2mwYYPlJGF{e2G7		NFHxS2syKGh?	NVTFfmQ5TE2VTx?=	MYrJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwM{Og{txO	NX\Ub\|V2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[0NlAxPjRpPkG2OFIxODZ2PD;hQi=>
HCT15	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3vHflQ5KGh?		MXrHTVUxRTBwOEKg{txO	NXvFc29jRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[3NlMzOjdpPkG2O\|I{OjJ5PD;hQi=>
NCI-H23	M1XQPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NV[4XZE5PDhiaB?=		NVfLU2F1T0l3ME2wMlkzKM7:TR?=	M3:we\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4N{KzNlI4Lz5zNkeyN\|IzPzxxYU6=
GM15850	MknwT4lv[XOnIFHzd4F6	MlyzNk42KM7:TR?=	MYi5OkBp	NV3MSmJ7TE2VTx?=	NFfSPIZKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIN{BtgXOrbnWgNVQh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjl{MUO2O{c,OTZ7MkGzOlc9N2F-
GM15850	MWPLbY5ie2ViQYPzZZk>	MUCyMlUh\|ryP	NFO5ZYE6PiCq	MWTEUXNQ	NH;CPFFKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgOUBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?=	NF\xUpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkmyNVM3Pyd-MU[5NlE{Pjd:L3G+
GM15850	M4i5cWtqdmG\|ZTDBd5NigQ>?	MXuyMlUh\|ryP	MoT6PVYhcA>?	MoW5SG1UVw>?	MXnJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKNDDsfZNqdmViMUKgZYNmfHmuYYTpc44hd2ZiRmjOJIdmdmV?	NHTnS3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkmyNVM3Pyd-MU[5NlE{Pjd:L3G+
GM15850	NVLaS\|QxU2mwYYPlJGF{e2G7	M3raO\|IvPSEQvF2=	M{TWc\|k3KGh?	MluySG1UVw>?	MYDJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKMzDsfZNqdmViOTDhZ4V1gWyjdHnvckBw\iCIWF6g[4Vv\Q>?	NIGwSng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkmyNVM3Pyd-MU[5NlE{Pjd:L3G+
GM15850	NUftUIJUU2mwYYPlJGF{e2G7	NHe1OHkzNjVizszN	NWfhUIZKQTZiaB?=	NIftV5RFVVOR	MUXJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKNDDsfZNqdmViODDhZ4V1gWyjdHnvckBw\iCIWF6g[4Vv\Q>?	NHvsc3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkmyNVM3Pyd-MU[5NlE{Pjd:L3G+
GM15850	MYLLbY5ie2ViQYPzZZk>	MomwNk42KM7:TR?=	MWq5OkBp	NWPmTVVUTE2VTx?=	NWj3[FJCUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFE3KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	NXTZXZhyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[5NlE{PjdpPkG2PVIyOzZ5PD;hQi=>
U937	NYm1OmxHTnWwY4Tpc44hSXO\|YYm=	NXf0RWVwPSEQvF2=	NHzHUlUzPCCq	M{Dkb2ROW09?	M1PuSGNmdGxiY4njcIUh[XK{ZYP0JIJ6KGGlY4XteYxifGmxbjDheEBUN0d{L12gdIhie2V?	NVjQW4JqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUewNFQ4OThpPkG3NFA1PzF6PD;hQi=>
H661	Ml3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWq0PEBp		M4Dsc2lEPTB;MTFOwG0>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzF3N{CwPUc,OTdzNUewNFk9N2F-
U937	NVHCW5NkTnWwY4Tpc44hSXO\|YYm=	M2P1fVUh\|ryP	MYKyOEBp	NEnu[W9FVVOR	MnnwTY5kemWjc3WgbY4hcGm\|dH;u[UBJOyCjY3X0fYxifGmxbh?=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzR2N{e1NEc,OTd2NEe3OVA9N2F-
U937	Ml;FSpVv[3Srb36gRZN{[Xl?	MnTJNUDPxE1?	MoLONlQhcA>?	M3vH[WROW09?	MU\F[oZm[3Rib36gZYxxcGFidIXieYxqdiCjY3X0fYxifGmxbh?=	NWLLXVRkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0OFc4PTBpPkG3OFQ4PzVyPD;hQi=>
RAW264.7	NEDMPHRHfW6ldHnvckBCe3OjeR?=	NFvaN\|cyOCEQvF2=	NHPvblYzPGh?	M3XYdZdifGW{	MlHHTY5pcWKrdHnvckBw\iCOUGOtd5RqdXWuYYTl[EBVVk[jbIDoZUBxem:mdXP0bY9vKHerdHigTWM2OCCxZjCwMlc3KM7:TR?=	M17UPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NEe3OVE5Lz5zN{S3O\|UyQDxxYU6=
RAW264.7	NHS5b5BHfW6ldHnvckBCe3OjeR?=	MWqxNEDPxE1?	NYPafGJlOjSq	M2XXVJdifGW{	NHvVNndKdmirYnn0bY9vKG:oIFzQV{1{fGmvdXzheIVlKE6RIIDyc4R2[3Srb36ge4l1cCCLQ{WwJI9nKDFwOEig{txO	MnK0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd2N{e1NVgoRjF5NEe3OVE5RC:jPh?=
SC9	NFTCXo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVfEZphOPDhiaB?=		NHf0XYtKSzVyPUCuOlA3KM7:TR?=	Mo\DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3MEeyNVkoRjF5NUC3NlE6RC:jPh?=
ST14A	Moe1SpVv[3Srb36gRZN{[Xl?	NGjy[FU2KG6P	NIPLeYc4OiCq		NWTPU29TUW6lcnXhd4UhcW5iUlXTWE9PWlOIIH3SUmEh\XiycnXzd4lwdg>?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV4NUm5N{c,OTd3NkW5PVM9N2F-
ST14A	NXLXT4xmTnWwY4Tpc44hSXO\|YYm=	NEfhSXQ2KG6P	NULtUXQ6PzJiaB?=		NUGxTG4xUW6lcnXhd4UhcW5iRULGNUBuWk6DIHX4dJJme3Orb36=	NFzQOoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W2OVk6Oyd-MUe1OlU6QTN:L3G+
PANC1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXKxJO69VQ>?			MV\JR\|UxRTBwNEWg{txO	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV6OEe0OEc,OTd3OEi3OFQ9N2F-
PANC1	Mn21SpVv[3Srb36gRZN{[Xl?	Mn7TNUDPxE1?	MViyOEBp		MYDJcoNz\WG\|ZTDpckBxOjGZQV[xM2NKWDFiZ3Xu[UBmgHC{ZYPzbY9v	MlzzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3OEi3OFQoRjF5NUi4O\|Q1RC:jPh?=
PANC1	MUHGeY5kfGmxbjDBd5NigQ>?	NEfWdHUyKM7:TR?=	MXyyOEBp		Mm\ZTY5kemWjc3WgbY4heDJ5a3nwNUBo\W6nIHX4dJJme3Orb36=	NGHxUYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W4PFc1PCd-MUe1PFg4PDR:L3G+
PT45	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkTuTWM2OD12IN88US=>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV6OEe0OEc,OTd3OEi3OFQ9N2F-
ACHN	Mn34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWKyNUBp		M1ToN2dKPTB;MD62OUDPxE1?	M2\CbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5Nk[yOlA3Lz5zN{[2NlYxPjxxYU6=
PC3	MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2PGTVIyKGh?		NWSyO\|FTT0l3ME2wMlcyKM7:TR?=	MmCxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4NkK2NFYoRjF5Nk[yOlA3RC:jPh?=
A431	NVrhVGFIS3m2b4TvfIlkKEG\|c3H5		M1znbFczKGh?		MVTJR\|UxRTRwMjFOwG0>	M2fnSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NkmxO\|Y{Lz5zN{[5NVc3OzxxYU6=
Cal27	NI\XOHZEgXSxdH;4bYMhSXO\|YYm=		NHf6Z\|Y4OiCq		NETLPFBKSzVyPUOuNkDPxE1?	NF3mRmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[5NVc3Oyd-MUe2PVE4PjN:L3G+
CCRF-CEM	MYDDfZRwfG:6aXOgRZN{[Xl?		M{GwfVczKGh?		NXn2cWZ1UUN3ME2wMlgh\|ryP	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ7MUe2N{c,OTd4OUG3OlM9N2F-
EOL1	MYjDfZRwfG:6aXOgRZN{[Xl?		NVXydItXPzJiaB?=		NVrPbnpLUUN3ME2xJO69VQ>?	NFja[Xk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[5NVc3Oyd-MUe2PVE4PjN:L3G+
Hec-1-A	NH;tUnVEgXSxdH;4bYMhSXO\|YYm=		NGfTdWY4OiCq		MUDJR\|UxRTFizszN	NXPLNJVPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2PVE4PjNpPkG3OlkyPzZ\|PD;hQi=>
HeLa	Mm\CT4lv[XOnIFHzd4F6	MVOxNEDPxE1?	MmDyN\|AhdWmw	MYHEUXNQ	NH\xSIlKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGhFSUNzIIfpeIghUUN3MDDv[kAxNjB{IN88US=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ7MUe2N{c,OTd4OUG3OlM9N2F-
RKOp21	NIDrcJNEgXSxdH;4bYMhSXO\|YYm=		MXu3NkBp		NGS3boNKSzVyPUGuO\|Yh\|ryP	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ7MUe2N{c,OTd4OUG3OlM9N2F-
Saos2	MXHDfZRwfG:6aXOgRZN{[Xl?		NUT0W\|FrPzJiaB?=		NGHJd2ZKSzVyPUKuN{DPxE1?	M2niOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NkmxO\|Y{Lz5zN{[5NVc3OzxxYU6=
SK-OV-3	MYTDfZRwfG:6aXOgRZN{[Xl?		NGG2NWE4OiCq		NVnxTYNMUUN3ME2yMlIh\|ryP	M3vnRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NkmxO\|Y{Lz5zN{[5NVc3OzxxYU6=
U87MG	MnjmR5l1d3SxeHnjJGF{e2G7		MmLZO\|IhcA>?		NX\RWHNQUUN3ME2xNUDPxE1?	M3;HflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NkmxO\|Y{Lz5zN{[5NVc3OzxxYU6=
NUGC3	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLCOUDPxE1?	M2HYTFI1KGh?		MkO3S2k2OD1{Lke5JO69VQ>?	MnzYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd7MES4OFMoRjF5OUC0PFQ{RC:jPh?=
CCD1059SK	M37WVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIrZfolKSzVyPUSzMlUh\|ryP	NIG3RVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK0O\|U2PCd-MUiyOFc2PTR:L3G+
HepG2	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIDP[GFKSzVyPUCuNFAxPiEQvF2=	M4rvZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MkS3OVU1Lz5zOEK0O\|U2PDxxYU6=
HT1080	NVvMSllnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHKXlJKSzVyPUCuNFAzPCEQvF2=	NF7QNo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK0O\|U2PCd-MUiyOFc2PTR:L3G+
SKBR3	M362[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXnzcHBDUUN3ME2wMlgh\|ryP	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ2N{W1OEc,OTh{NEe1OVQ9N2F-
SNB78	NIDlW45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY\XfZVsTUN3ME2xOkDPxE1?	NH\GTpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK0O\|U2PCd-MUiyOFc2PTR:L3G+
SQ20B	MoC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTNizszN	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ2N{W1OEc,OTh{NEe1OVQ9N2F-
St4	NEW2d4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEX3U\|FGSzVyPUWuNkDPxE1?	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ2N{W1OEc,OTh{NEe1OVQ9N2F-
MCF7	NHP5NZVHfW6ldHnvckBCe3OjeR?=	M3i5[lExKM7:TR?=	MlHNPEBp	NGHXWoFFVVOR	NEDBTmJKdmS3Y4Tpc44hd2ZidIXieYxqdiCqeYDldoFk\XS7bHH0bY9v	NIfJd3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK2PVIzPid-MUiyOlkzOjZ:L3G+
HEK293	MnT5T4lv[XOnIFHzd4F6		M1P0RlEhcA>?	MnfjSG1UVw>?	MYfJcohq[mm2aX;uJI9nKEiGQVOxJJdqfGhiSVO1NEBw\iByLkCzJO69VQ>?	NFiwWYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEOwPFU3Oyd-MUizNFg2PjN:L3G+
HEK293	MXXLbY5ie2ViQYPzZZk>		NYfUVm5tOSCq	M2LiZ2ROW09?	NHS3UnlKdmirYnn0bY9vKG:oIFjERWM{KHerdHigTWM2OCCxZjCwMlA2PyEQvF2=	NHTNZ2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEOwPFU3Oyd-MUizNFg2PjN:L3G+
G401	NV[0RYFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXu3NkBp	NF;2ZmVFVVOR	MlXFTWM2OD1zIN88US=>	NVfFRlNRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizO\|A{PzNpPkG4N\|cxOzd\|PD;hQi=>
HeLa	MoLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4jyN\|czKGh?	MUPEUXNQ	NGTRbmVKSzVyPUCuOFYh\|ryP	NWL4N\|N1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizO\|A{PzNpPkG4N\|cxOzd\|PD;hQi=>
Human renal epithelial cell	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXW3NkBp	M3HlTmROW09?	NHLJTY5KSzVyPUG0JO69VQ>?	MmH0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh\|N{CzO\|MoRjF6M{ewN\|c{RC:jPh?=
U937	NYDSdo0xTnWwY4Tpc44hSXO\|YYm=	NIHxSJY2KM7:TR?=	NI\FUnczPCCq		NXfybFQ3UW6mdXP0bY9vKG:oIHjpd5RwdmViSESgbJlx\XKjY3X0fYxifGmxbh?=	M2TBOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{ixNlM5Lz5zOEO4NVI{QDxxYU6=
U937	MWnGeY5kfGmxbjDBd5NigQ>?	NUC2U21qPSEQvF2=	M2\UWFI1KGh?		NGDKN45KdmS3Y4Tpc44hd2ZiYXzwbIEhfHWkdXzpckBpgXCncnHj[ZR6dGG2aX;u	NI\scXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEO4NVI{QCd-MUizPFEzOzh:L3G+
U937	NF3uTWFHfW6ldHnvckBCe3OjeR?=	M1\G[\|Uh\|ryP	NXHkRlh5OjRiaB?=		MkPmTY5lfWO2aX;uJI9nKHB{MTDlfJBz\XO\|aX;u	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDN6MUKzPEc,OTh\|OEGyN\|g9N2F-
U937	MlLrSpVv[3Srb36gRZN{[Xl?	MVS1JO69VQ>?	MkizNlQhcA>?		Mn\oTY5lfWO2aX;uJI9nKGGyb4D0c5Nqew>?	NIfoTpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEO4NVI{QCd-MUizPFEzOzh:L3G+
U937	NYjXb41rTnWwY4Tpc44hSXO\|YYm=	M{\0WlUh\|ryP	M17sNFI1KGh?		Ml7RTY5lfWO2aX;uJI9nKGe{YX71cI9kgXSrYzDkbYZn\XKnboTpZZRqd25?	MlrCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh\|OEGyN\|goRjF6M{ixNlM5RC:jPh?=
U937	Mke5T4lv[XOnIFHzd4F6	NXrabZhvPSEQvF2=	NH;VNYUzPCCq		NGXBWFBKdmirYnn0bY9vKG:oIHj1cYFvKEiGQVOx	MnvmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh\|OEGyN\|goRjF6M{ixNlM5RC:jPh?=
U937	MnnST4lv[XOnIFHzd4F6	NULRRppyPSEQvF2=	NWLhc3o2OjRiaB?=		NFTxVJNKdmirYnn0bY9vKG:oIHj1cYFvKEiGQVO0	Ml;lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh\|OEGyN\|goRjF6M{ixNlM5RC:jPh?=
HEK-TE	MmfUSpVv[3Srb36gRZN{[Xl?	NWX1W2pxPSEQvF2=	NGfJNFE3cA>?	NWjzZZVwTE2VTx?=	MUnJcoNz\WG\|ZTDpckBpcXO2b37lJGg{KGGlZYT5cIF1cW:w	NFXUUGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOESzOFE1PCd-MUi0N\|QyPDR:L3G+
HPDE6c7	Mo\QR5l1d3SxeHnjJGF{e2G7	NVTafVJYPTBizszN	NU\PVmp6PzJiaB?=	MUPEUXNQ	M3ziNGlEPTB;MT6zJO69VQ>?	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR7NES2N{c,OTh2OUS0OlM9N2F-
Human microvascular epithelial cell	M1TSSmN6fG:2b4jpZ{BCe3OjeR?=	MYi1NEDPxE1?	MWq3NkBp	NXXueWE{TE2VTx?=	NWr5V3pyUUN3ME2xMlMh\|ryP	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR7NES2N{c,OTh2OUS0OlM9N2F-
Hup T3	MWfDfZRwfG:6aXOgRZN{[Xl?	MnzSOVAh\|ryP	NFPqVY44Omh?	NITmeVNFVVOR	M{faZmlEPTB;MD64JO69VQ>?	MoW4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2OUS0OlMoRjF6NEm0OFY{RC:jPh?=
Mia Paca2	MleyR5l1d3SxeHnjJGF{e2G7	NYm0NmkxPTBizszN	MVi3Nog>	MlHISG1UVw>?	MVzJR\|UxRTFwMTFOwG0>	NXfkUG9zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0PVQ1PjNpPkG4OFk1PDZ\|PD;hQi=>
Panc 04.03	MmDXR5l1d3SxeHnjJGF{e2G7	MknlOVAh\|ryP	MnPaO\|Jp	MWrEUXNQ	NITHVoxKSzVyPUGuNkDPxE1?	NF:5b3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOES5OFQ3Oyd-MUi0PVQ1PjN:L3G+
SU 86.86	MV7DfZRwfG:6aXOgRZN{[Xl?	MX[1NEDPxE1?	M33TSFczcA>?	NHK4OJNFVVOR	MXzJR\|UxRTFwMzFOwG0>	M3zwPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NEm0OFY{Lz5zOES5OFQ3OzxxYU6=
HEK293	Mke4T4lv[XOnIFHzd4F6		NIj0dFA{KGh?		MkSxTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDISGFEPiCneIDy[ZN{cW:wIIfpeIghUUN3MDDv[kAxNjBzOTFOwG0>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV3OE[2PUc,OTh3NUi2Olk9N2F-
HeLa	M{jHe2tqdmG\|ZTDBd5NigQ>?		Mmr1NkBp		Mm\nTY5pcWKrdHnvckBw\iCwdXPs[YFzKEiGQVOge4l1cCCLQ{WwJI9nKDBwMEizJO69VQ>?	M3na[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUW4OlY6Lz5zOEW1PFY3QTxxYU6=
RAW264.7	MU\GeY5kfGmxbjDBd5NigQ>?	M3fiTlIh\|ryP	M3rt[\|MvPSCq	NFTQZZZFVVOR	MYPBcpRqdWGuYYLpZYwh[WO2aY\peJkh[WejaX7zeEBRdGG\|bX;kbZVuKG[jbHPpdIFzfW1iaX7m[YN1\WRid3n0bEBKSzVyIH;mJFAvOTFizszN	NX32N2FRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2OFQ6PjlpPkG4OlQ1QTZ7PD;hQi=>
NB4			MYq0PIg>	NFexWHRFVVOR	NIPuR\|NKSzVyPUCuOkDPxE1?	NXXiU4xuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi3NlM{PDlpPkG4O\|I{OzR7PD;hQi=>
HEK293	NWfuXlRxTnWwY4Tpc44hSXO\|YYm=	M{LqOlExKM7:TR?=	MoDrNlQhcA>?	M17uTWROW09?	MlKzRYN1cX[jdHnvckBw\iCvb4Xz[UBYdnR\|YTDzbYdv[Wyrbneg[ZhxemW\|c3Xk	NFfiNGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCyNlY4PSd-MUmwNlI3PzV:L3G+
HCT116	NYfl[IE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1vGTlczcA>?	M1jkVmROW09?	NXPK[YxsUUN3ME2wMlMyKM7:TR?=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTB6NEK5OEc,OTlyOESyPVQ9N2F-
HeLa	NXfPR\|k6U2mwYYPlJGF{e2G7	NXnucmY{OiEQvF2=	M{mxblMxKG2rbh?=	MofDSG1UVw>?	MUHJcohq[mm2aX;uJI9nKEiGQVOyJIlvKGi3bXHuJGhmVGFiY3XscJMhf2m2aDDJR\|UxKG:oIECuNUDPxE1?	MnPPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyOESyPVQoRjF7MEi0Nlk1RC:jPh?=
IGROV1	MkTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWS3NkBp	MYfEUXNQ	M4CySWlEPTB;Mj6yJO69VQ>?	NX7FTmFERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwPFQzQTRpPkG5NFg1Ojl2PD;hQi=>
IGROV1	MXTLbY5ie2ViQYPzZZk>	NUO0ZppsPSEQvF2=	NGrXO3EzPCCq	NUD0RnlFTE2VTx?=	M2LnOGlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCyNUOgZYNmfHmuYYTpc44>	NGrmNGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUC4OFI6PCd-MUmwPFQzQTR:L3G+
IGROV1	NH7VUoxMcW6jc3WgRZN{[Xl?	NE\ufGwyOCEQvF2=	NXT6WJpsPCCq	M1HJOWROW09?	MoPFTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGirc4TvcoUuUDRiYXPleJlt[XSrb36=	NHzTd249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUC4OFI6PCd-MUmwPFQzQTR:L3G+
IGROV1	NUjqZYxFU2mwYYPlJGF{e2G7	M1\yR\|ExKM7:TR?=	MlTuOEBp	NXLCcWo{TE2VTx?=	M1fafmlvcGmkaYTpc44hd2ZiSFTBR\|Yh[XO\|ZYPz[YQh[XNiYXzwbIEufHWkdXzpckBi[2W2eXzheIlwdg>?	M4HNTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEi0Nlk1Lz5zOUC4OFI6PDxxYU6=
T24	MknpT4lv[XOnIFHzd4F6		Mk\QN{Bp		NELMOodKdmS3Y4Tpc44hd2ZiaHnzeI9v\SCKMzDhZ4V1gWyjdHnvckB4cXSqIFXDOVAhd2ZiMD6xNkDPxE1?	NG\VeoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUC4OFM6PSd-MUmwPFQ{QTV:L3G+
T24	MXzLbY5ie2ViQYPzZZk>		MlzFN{Bp		NGe0TXVKdmS3Y4Tpc44hd2ZiYXzwbIEhfHWkdXzpckBi[2W2eXzheIlwdiC5aYToJGVEPTBib3[gNE4zPSEQvF2=	NHjqSlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUC4OFM6PSd-MUmwPFQ{QTV:L3G+
HeLa	MkTaT4lv[XOnIFHzd4F6		NHjjcpEyPSCvaX6=	MYPEUXNQ	MYDJcohq[mm2aX;uJI9nKEiGQVO2JIZzd21iboXjcIVieiCneITyZYN1KHerdHigTWM2OCCxZjCwMlA5PTVizszN	NXTVTZNERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwPVM5QDRpPkG5NFk{QDh2PD;hQi=>
HeLa	M2LaTmtqdmG\|ZTDBd5NigQ>?		NHy1PHIyPSCvaX6=	NW\XWmo1TE2VTx?=	M4XrXmlvcGmkaYTpc44hd2ZiSFTBR\|gh\nKxbTDueYNt\WG{IHX4eJJi[3Rid3n0bEBKSzVyIH;mJFEvQDZizszN	NHXSenE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUC5N\|g5PCd-MUmwPVM5QDR:L3G+
NCI-H69	MnfER5l1d3SxeHnjJGF{e2G7		MXG3NkBp	NHr3TIZFVVOR	NYjRUWZ1UUN3ME2yMlA3KM7:TR?=	MonnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyOUO4PFQoRjF7MEmzPFg1RC:jPh?=
SKMES1	NUXGfoJXS3m2b4TvfIlkKEG\|c3H5		MY[3NkBp	MVXEUXNQ	NUTZXHlIUUN3ME2yMlQzKM7:TR?=	NGjNT2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUC5N\|g5PCd-MUmwPVM5QDR:L3G+
S2	Mkn4T4lv[XOnIFHzd4F6	MUWwMlEuOTBizszN	M{PjVlEhcA>?		M33FcGlvcGmkaYTpc44hd2ZiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJGhFSUNzIHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOC5yNUmg{txO	Ml62QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl\|MUe0OVAoRjF7M{G3OFUxRC:jPh?=
SHSY5Y	MYLLbY5ie2ViQYPzZZk>	NE[1VVMyOCEQvF2=	MUO0PEBp	MUDEUXNQ	NIL5OG1KdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR\|UxKG:oIECuOUDPxE1?	MmmyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl\|NESxO\|UoRjF7M{S0NVc2RC:jPh?=
SHSY5Y	MnzOR5l1d3SxeHnjJGF{e2G7	MYCxNEDPxE1?	NWj1cXJmPDhiaB?=	MV3EUXNQ	NGrXT5dKSzVyPUKg{txO	NWPxdYZWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmzOFQyPzVpPkG5N\|Q1OTd3PD;hQi=>
DMS114	MoPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlrVOFghcA>?		MV3HTVUxRTJwOTFOwG0>	MmXVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl2MUmyNFUoRjF7NEG5NlA2RC:jPh?=
HBC5	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYPiV5NvPDhiaB?=		NGnsVYpIUTVyPUG3JO69VQ>?	NYLTUXVPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0NVkzODVpPkG5OFE6OjB3PD;hQi=>
SNB78	NVLWTndDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MW[0PEBp		M1zieWdKPTB;MU[g{txO	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTRzOUKwOUc,OTl2MUmyNFU9N2F-
HeLa	NYLz[GpkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGnkNJg4OiCq	MnzQSG1UVw>?	Mn3nTWM2OD1yLkS2JO69VQ>?	NEf0dHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUS0NVg1Pid-MUm0OFE5PDZ:L3G+
BHK	NWO3d213U2mwYYPlJGF{e2G7	MkDJOUDPxE1?	NIHMWmkzPCCq	MlXpSG1UVw>?	M33LbmlvcGmkaYTpc44hd2ZiSFTBR\|ch\XiycnXzd4VlKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJBt[XOvYTDt[Y1jemGwZTDG[IVtfGF3MEigR2ZVWiCycn;0[Ylv	NIf5dnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUm2Olc5QSd-MUm5OlY4QDl:L3G+
CFBE41o-	MU\LbY5ie2ViQYPzZZk>	M{H3PVUh\|ryP	NHLUVI85KGh?	NVTSfGVjTE2VTx?=	NWXEUG9WUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHj5dIVz[WOndInsZZRqd25ib3[gbIl{fG:wZTDINy=>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTl4Nke4PUc,OTl7Nk[3PFk9N2F-
CFBE41o-	NUHXNI5GU2mwYYPlJGF{e2G7	NXfnRodnPSEQvF2=	M32w[\|QhcA>?	MVTEUXNQ	Ml75TY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIH31eIFvfCCIZHXseIE2ODhiQ1\UVkBxem:2ZXnuJIxmfmWu	NHvE[nQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUm2Olc5QSd-MUm5OlY4QDl:L3G+
CFBE41o-	M1z3V2tqdmG\|ZTDBd5NigQ>?	NHTXR4UyKM7:TR?=	NETzT2YyKGh?	MmO0SG1UVw>?	MYjJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iQ1\UVkBxem:2ZXnuJIxmfmWu	NV3WUHJyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5OlY4QDlpPkG5PVY3Pzh7PD;hQi=>
Primary bronchial epithelial cell	M4LMZWtqdmG\|ZTDBd5NigQ>?	MnPlNUDPxE1?	NXSwVW9iOjRiaB?=	MYfEUXNQ	NHnP[Y9KdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnu[JVkfGmxbjDv[kBufXSjboSgSoRmdHSjNUC4JGNHXFJicILveIVqdiCjcHnjZYwhe3W{ZnHj[UBtd2OjbHn6ZZRqd25?	NHmyOGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUm2Olc5QSd-MUm5OlY4QDl:L3G+
CFBE41o-	NVjCVFlWU2mwYYPlJGF{e2G7	NXPhOVZbOSEQvF2=	MUG1JIRigXN?	Mln4SG1UVw>?	NET1XGlKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJN1[WKrbHn6ZZRqd25ib3[gSoRmdHSjNUC4JGNHXFJicILveIVqdg>?	M2fJOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OU[2O\|g6Lz5zOUm2Olc5QTxxYU6=
CFBE41o-	NH7MPXlMcW6jc3WgRZN{[Xl?	MX6xJO69VQ>?	M{HQZlI1KGh?	NGHh[2JFVVOR	NWrRU\|hkUW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBH\GWudHG1NFghS0[WUjDwdo91\WmwIITyZYZncWOtaX7n	M2PselxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OU[2O\|g6Lz5zOUm2Olc5QTxxYU6=
CFBE41o-	NELtN5BMcW6jc3WgRZN{[Xl?	MoK5OUDPxE1?	NHPFRYUzPCCq	MlTPSG1UVw>?	MnrjTY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDyZZRmKG:oIH3heJVz[XSrb36gc4YhS0[WUjDwdo91\WmwIITvJIl1eyCpbInjc4Zwem1?	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTl4Nke4PUc,OTl7Nk[3PFk9N2F-
CFBE41o-	MUXLbY5ie2ViQYPzZZk>	NUHUfoc4PSEQvF2=	NE\XeJozPCCq	M3;HUmROW09?	MY\Jcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIIP0ZYJqdGm2eTDv[kBH\GWudHG1NFghS0[WUjDwdo91\Wmw	NInwOWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUm2Olc5QSd-MUm5OlY4QDl:L3G+
CFBE41o-	NGXxbmZMcW6jc3WgRZN{[Xl?	NXfKWIoyPSEQvF2=	MYmyOEBp	MXfEUXNQ	M4\LdmlvcGmkaYTpc44hd2ZiSFTBR\|ch[XO\|ZYPz[YQh[XNiY3;ydoVkfGmxbjDv[kBufXSjboSgSoRmdHSjNUC4JGNHXFJidILh[oZq[2urbnegeI8h[2WubDDzeZJn[WOnIHHzJIdtgWOxZn;ycS=>	NFrZfJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUm2Olc5QSd-MUm5OlY4QDl:L3G+
Primary bronchial epithelial cell	M{HsUGtqdmG\|ZTDBd5NigQ>?	MmDBOUDPxE1?	M{i1W\|I1KGh?	M{fqN2ROW09?	MWrJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6mdXP0bY9vKG:oIH31eIFvfCCIZHXseIE2ODhiQ1\UVkBxem:2ZXnuJIFxcWOjbDDzeZJn[WOnIHzvZ4FtcXqjdHnvci=>	M{PzdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OU[2O\|g6Lz5zOUm2Olc5QTxxYU6=
Primary bronchial epithelial cell	Mn20T4lv[XOnIFHzd4F6	NFj5PGEyKM7:TR?=	MYS5OkBp	M3jMTWROW09?	MX3Jcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIIPoc5J1KGOrcnP1bZQh[3W{cnXueJM>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTl4Nke4PUc,OTl7Nk[3PFk9N2F-
BxPC3	NVHyR4gyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYnvcGw1PzJiaB?=		MXTJR\|UxRTJwNzFOwG0>	Mn\ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNEO3O\|goRjJyMUSzO\|c5RC:jPh?=
CAL27	NFrtSm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2\UeVczKGh?		NEHBS2NKSzVyPUOuO\|Ih\|ryP	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF2M{e3PEc,OjBzNEO3O\|g9N2F-
Capan1	MnnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWC3NkBp		MYLJR\|UxRTdwMzFOwG0>	Mor6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNEO3O\|goRjJyMUSzO\|c5RC:jPh?=
HCC827	NE\PPFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFfGRVQ4OiCq		MXnJR\|UxRTFwODFOwG0>	Mn7zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNEO3O\|goRjJyMUSzO\|c5RC:jPh?=
LNCAP	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIi5NlA4OiCq		Mmi2TWM2OD1yLkW4JO69VQ>?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF2M{e3PEc,OjBzNEO3O\|g9N2F-
NCI-H2122	NH34NppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVH1UoVTPzJiaB?=		NX\WRVJlUUN3ME23MlUh\|ryP	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF2M{e3PEc,OjBzNEO3O\|g9N2F-
NCI-H358	MmXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NV\tSZhqPzJiaB?=		MYrJR\|UxRTJwNTFOwG0>	MlrXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNEO3O\|goRjJyMUSzO\|c5RC:jPh?=
SCC15	NXT2d5pbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{TLd\|czKGh?		MnzrTWM2OD1{LkS5JO69VQ>?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF2M{e3PEc,OjBzNEO3O\|g9N2F-
SCC25	M3yze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{S2OlczKGh?		NG\2PY9KSzVyPUGuPVMh\|ryP	NVHGPI9IRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxOFM4PzhpPkKwNVQ{Pzd6PD;hQi=>
SKHEP1	NHTFTpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlmyO\|IhcA>?		NVvqWnlQUUN3ME2zMlQ3KM7:TR?=	MnnaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNEO3O\|goRjJyMUSzO\|c5RC:jPh?=
BJ	NX;TVWhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTjNVAxKM7:TR?=	M3PXUVQ5KGh?	MWrEUXNQ	NHzBfHdIem:5dHigbY5pcWKrdHnvckBifCByLkC1JJRwKDFyMDD1US=>	NVyzSXNxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxOFM5PDBpPkKwNVQ{QDRyPD;hQi=>
MUF	M4DQbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWO1O4hkOTByIN88US=>	NH7lVpg1QCCq	NIHzRpZFVVOR	NWf1TZdzT3Kxd4ToJIlvcGmkaYTpc44h[XRiMD6wOUB1dyBzMECgeW0>	M37NflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUSzPFQxLz5{MEG0N\|g1ODxxYU6=
Caco-2	NXTpN3hyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mke5NVAxKM7:TR?=	NVT5bYFkPDiq	NW\sfXZyTE2VTx?=	NVW5O\|NRUUN3ME24MlEh\|ryP	Mnj4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNEO4OFAoRjJyMUSzPFQxRC:jPh?=
Caco-2	MVHLbY5ie2ViQYPzZZk>	NIT6dFU2KM7:TR?=	MV60JIg>	NHHqPJpFVVOR	M4jiXmlv\HWldHnvckBw\iCKRFHDMY1m\GmjdHXkJIhqe3SxbnWgZYNmfHmuYYTpc44hUUN3MDDv[kAxNjB\|NzFOwG0>	M{W3NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUSzPFQxLz5{MEG0N\|g1ODxxYU6=
Caco-2	MoT3T4lv[XOnIFHzd4F6	MXKwMlMyPiCwTTD0c{A{OS54IN88US=>	NEnBUFg1KGh?	NHfodYRFVVOR	NIDQZ4hGgCC4aY\vJIlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{Gge4l1cCCLQ{WwJI9nKDBwMUG5JO69VQ>?	NGP2RpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0N\|g1OCd-MkCxOFM5PDB:L3G+
Caco-2	MoTCT4lv[XOnIFHzd4F6	M3XGSFAvOzF4IH7NJJRwKDNzLk[g{txO	NH\DSog1KGh?	MWnEUXNQ	Mom3SZghfmm4bzDpcohq[mm2aX;uJI9nKGi3bXHuJGhFSUN\|IIfpeIghUUN3MDDv[kAxNjF2NzFOwG0>	MkDEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNEO4OFAoRjJyMUSzPFQxRC:jPh?=
Caco-2	MXfLbY5ie2ViQYPzZZk>	MYG2MlMzKG6PIITvJFY{OiEQvF2=	NXHZbXc2PCCq	MV7EUXNQ	NUjJW2xzTXhidnn2c{BqdmirYnn0bY9vKG:oIHj1cYFvKEiGQVO1JJdqfGhiSVO1NEBw\iBzMj62JO69VQ>?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF2M{i0NEc,OjBzNEO4OFA9N2F-
Caco-2	MYXLbY5ie2ViQYPzZZk>	MXq2MlMzKG6PIITvJFY{OiEQvF2=	MkTNOEBp	MUDEUXNQ	MWLFfEB3cX[xIHnubIljcXSrb36gc4YhcHWvYX6gTGRCSzdid3n0bEBKSzVyIH;mJFQyKM7:TR?=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF2M{i0NEc,OjBzNEO4OFA9N2F-
Caco-2	MoPvT4lv[XOnIFHzd4F6	M1viTFAvOzF4IH7NJJRwKDNzLk[g{txO	NI\RUoM1KGh?	NG\sOJlFVVOR	NVnzSoR1TXhidnn2c{BqdmirYnn0bY9vKG:oIHj1cYFvKEiGQVO2	M3u1ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUSzPFQxLz5{MEG0N\|g1ODxxYU6=
HepG2	M1zDbGtqdmG\|ZTDBd5NigQ>?	NEHSbmk2KM7:TR?=	NUDQU5c6Pmh?	MVPEUXNQ	MYnJcoR2[3Srb36gc4YhUESDQz3t[YRq[XSnZDDobZN1d26nIHHj[ZR6dGG2aX;u	M4fSfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUSzPFQxLz5{MEG0N\|g1ODxxYU6=
HepG2	NHPIS3pMcW6jc3WgRZN{[Xl?	MmnpOUDPxE1?	MVW2bC=>	NGTL[JRFVVOR	M4\HPWlv\HWldHnvckBw\iCKRFHDMY1m\GmjdHXkJIhqe3SxbnWgbJlx\XKjY3X0fYxifGmxbh?=	NXXtbIFQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxOFM5PDBpPkKwNVQ{QDRyPD;hQi=>
HepG2	NX7kNWhDU2mwYYPlJGF{e2G7	NHKxcGE2KM7:TR?=	MWW2bC=>	NXLTU2RlTE2VTx?=	MXrJcoR2[3Srb36gc4YhUESDQz3t[YRq[XSnZDDhcJBp[S22dXL1cIlvKGGlZYT5cIF1cW:w	NHrLNpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0N\|g1OCd-MkCxOFM5PDB:L3G+
HepG2	M1HFd2tqdmG\|ZTDBd5NigQ>?	MkfvOUDPxE1?	MXm2bC=>	MXPEUXNQ	M{P3Rmlv\HWldHnvckBw\iCKRFHDMY1m\GmjdHXkJGg{N0h2IHjpd5RwdmViYXPleJlt[XSrb36=	M1vhbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUSzPFQxLz5{MEG0N\|g1ODxxYU6=
COLO205	NGHGZW1McW6jc3WgRZN{[Xl?	NHW3eVIyOCEQvF2=	NVe4O4s5OjRiaB?=	M{W4bGROW09?	MmnzTY5pcWKrdHnvckBw\iCKRFHDNUBie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gbIl{fG:wZTDIN{Bi[2W2eXzheIlwdiC5aYToJGlEPTBib3[gNk4zKM7:TR?=	NVm1XmJ[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0OVE{PzhpPkKwOFUyOzd6PD;hQi=>
SCC4	NUPCVGZVU2mwYYPlJGF{e2G7	MWKxJO69VQ>?	MUCyOIg>		M3nYTGlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjD0eYJ2dGmwIHHj[ZR6dGG2aX;u	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODR3MkKyOUc,OjB2NUKyNlU9N2F-
SCC4	NF\wOplMcW6jc3WgRZN{[Xl?	NGLNeVkyKM7:TR?=	MUKyOIg>		MoTiTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViYXPleJlt[XSrb36=	NGjvO\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MES1NlIzPSd-MkC0OVIzOjV:L3G+
SCC4	Mm\iSpVv[3Srb36gRZN{[Xl?	NXWyTJk5OSEQvF2=	MXm1JI1qdg>?		NGDlVm9C\2:waYP0JIFkfGm4aYT5JIF1KF[GUjDhd5Nme3OnZDDhd{BqdmS3Y4Tpc44hd2ZiQ2nQNlQh\2WwZTDlfJBz\XO\|aX;u	Mn;6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2NUKyNlUoRjJyNEWyNlI2RC:jPh?=
NB4	Mm\iSpVv[3Srb36gRZN{[Xl?	NF7jSnM2KM7:TR?=	NGL4NogzPCCq	MmHiSG1UVw>?	NVPXeIRXS2WubDDjfYNt\SCjcoLld5Qh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gZYNkfW23bHH0bY9vKGG2IIDy[U1IOSCyaHHz[S=>	NEn6O3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MES5NVQ1OCd-MkC0PVE1PDB:L3G+
NB4	NUnDfVlbU2mwYYPlJGF{e2G7	M4jwUlUh\|ryP	NWPqN25ZOjRiaB?=	M4\jRWROW09?	NYPKe2ZXUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIFk\XS7bHH0[UB1fWK3bHnuJIxmfmWu	NFfwWHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MES5NVQ1OCd-MkC0PVE1PDB:L3G+
NB4	NEPqOWdHfW6ldHnvckBCe3OjeR?=	M1jWdFUh\|ryP	MYiyOEBp	M3jwfWROW09?	M1nYUGlv\HWldHnvckBw\iCyMkHXRWYyN0OLUEGg[ZhxemW\|c3nvci=>	NIr0U3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MES5NVQ1OCd-MkC0PVE1PDB:L3G+
NB4	NH\xU4xMcW6jc3WgRZN{[Xl?	NGHQcVg2KM7:TR?=	NFHjRlQzPCCq	MkOwSG1UVw>?	NEPjTXZKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIN{Bi[2W2eXzheIlwdg>?	M2fxOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEmxOFQxLz5{MES5NVQ1ODxxYU6=
NUGC3	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3vEfWdKPTB;Mj65OEDPxE1?	M4XWfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEWwPVcyLz5{MEi1NFk4OTxxYU6=
A549	NXm1SGRZTnWwY4Tpc44hSXO\|YYm=	MWK1JO69VQ>?	M3TR[lMhcA>?	Mn[zSG1UVw>?	NGToUGFKdmS3Y4Tpc44hd2ZiYYX0c5Bp[We7IHnuJIh2dWGwIFG1OFkh[2WubIOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iTFOzTWk>	MnTKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6NUWyNFgoRjJyOEW1NlA5RC:jPh?=
HUT78	M17lPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3zsNlczKGh?	MU\EUXNQ	MUXHTVUxRTBwMzFOwG0>	Mn\aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6OESyNFgoRjJyOEi0NlA5RC:jPh?=
U937	NV3CWXFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkfQO\|IhcA>?	M{XwTWROW09?	M2\uVWdKPTB;MD6zPUDPxE1?	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh6NEKwPEc,OjB6OESyNFg9N2F-
A431	MnHOR5l1d3SxeHnjJGF{e2G7		MYm3NkBp		NXn3bFZlS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTR\|MTDj[YxteyCxdnXy[ZhxemW\|c3nu[{BGT0[UIIfpeIghUUN3MDDv[kA1NjJizszN	NFXsRmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUC4NFYzQSd-MkGwPFA3Ojl:L3G+
A549	M2LEcWN6fG:2b4jpZ{BCe3OjeR?=		NGHHd5Y4OiCq		MkX2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{BwfmW{ZYjwdoV{e2mwZzDISGFEKHerdHigTWM2OCCxZjCxMlgh\|ryP	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB6ME[yPUc,OjFyOEC2Nlk9N2F-
CAL27	MVTDfZRwfG:6aXOgRZN{[Xl?		NW[0S\|dtPzJiaB?=		NG\WdGZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBESUx{NzDj[YxteyCxdnXy[ZhxemW\|c3nu[{BGT0[UIIfpeIghUUN3MDDv[kA{NjJizszN	NH\rRpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUC4NFYzQSd-MkGwPFA3Ojl:L3G+
HeLa	M4nh[2N6fG:2b4jpZ{BCe3OjeR?=		NWLlfo5KPzJiaB?=		MnLFR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{BwfmW{ZYjwdoV{e2mwZzDISGFEKHerdHigTWM2OCCxZjCxMlUh\|ryP	M1zoOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMEiwOlI6Lz5{MUC4NFYzQTxxYU6=
Sf21	MWrLbY5ie2ViQYPzZZk>		MlG0N{Bp		NU\1dXUxUW6qaXLpeIlwdiCxZjDGcIFoKHSjZ3fl[EBpfW2jbjDy[YNwdWKrbnHueEBJTEGFODDlfJBz\XO\|ZXSge4l1cCCLQ{WwJI9nKDFwMjFOwG0>	M3vYWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMEiwOlI6Lz5{MUC4NFYzQTxxYU6=
SKBR3	NE\2WY1EgXSxdH;4bYMhSXO\|YYm=		MYm3NkBp		MY\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT2JTOyClZXzsd{BwfmW{ZYjwdoV{e2mwZzDISXIzKHerdHigTWM2OCCxZjCyMlYh\|ryP	NVLJR2tjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGwPFA3OjlpPkKxNFgxPjJ7PD;hQi=>
SKOV3	NEHxTHFEgXSxdH;4bYMhSXO\|YYm=		M1T4Z\|czKGh?		MVHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT29XOyClZXzsd{BwfmW{ZYjwdoV{e2mwZzDISXIzKHerdHigTWM2OCCxZjCyMlIh\|ryP	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB6ME[yPUc,OjFyOEC2Nlk9N2F-
COR-L23	NIX4WJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfONVAh\|ryP	NFz2bWI4OiCq	MWXEUXNQ	NFPCZWlIUTVyPUGuNUDPxE1?	NFixTIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUC4NFY1Pyd-MkGwPFA3PDd:L3G+
DU145	NFT1eIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYH2VHBbOTBizszN	MmrHO\|IhcA>?	MliySG1UVw>?	Mn23S2k2OD1zLkC1JO69VQ>?	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB6ME[0O{c,OjFyOEC2OFc9N2F-
LoVo	M{jQfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXVUYt5OTBizszN	NFzw[IU4OiCq	M2nvTGROW09?	NH;VNmdIUTVyPUGuO{DPxE1?	MmPTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFyOEC2OFcoRjJzMEiwOlQ4RC:jPh?=
MCR5-SV2	NUDsdVhkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWOxNEDPxE1?	M{fX[\|czKGh?	M3XFOmROW09?	MUTHTVUxRTJwMTFOwG0>	MoXVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFyOEC2OFcoRjJzMEiwOlQ4RC:jPh?=
HCT116	MXLLbY5ie2ViQYPzZZk>	NIDHPJg{OCEQvF2=	NVTxSXpuOzBiaB?=	MkLsSG1UVw>?	NVXtV4J6UW6qaXLpeIlwdiCxZjDISGFEPiCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4Yh[WyyaHGteJVjfWyrbjDhZ4V1gWyjdHnvci=>	NGrwNY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUC4NFY1Pyd-MkGwPFA3PDd:L3G+
HCT116	NXzQe5d[U2mwYYPlJGF{e2G7	Mmf6N\|Ah\|ryP	M{CzclMxKGh?	M{fYc2ROW09?	MkXZTY5pcWKrdHnvckBw\iCKRFHDNUBie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gbIl{fG:wZTDIN2s6KGGlZYT5cIF1cW:w	NHL4S2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUC4NFY1Pyd-MkGwPFA3PDd:L3G+
U937	NUDKfpdqU2mwYYPlJGF{e2G7	MXS1JO69VQ>?	MYKyOEBp	MX\EUXNQ	MUTJcohq[mm2aX;uJI9nKGirc4TvcoUh[WOndInseJJidnOoZYLhd4Uh[XO\|ZYPz[YQh[XNiaX7jdoVie2Vib3[gZYNmfHmuYYTpc44hd2ZiaHnzeI9v\SCKMzDheEBMQQ>?	MoDGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{OUK0PVIoRjJzMkmyOFkzRC:jPh?=
U937	MlvNT4lv[XOnIFHzd4F6	M1HJelUh\|ryP	M4rlRVI1KGh?	MkS4SG1UVw>?	MV3Jcohq[mm2aX;uJI9nKGirc4TvcoUh[WOndInseJJidnOoZYLhd4Uh[XO\|ZYPz[YQh[XNiaX7jdoVie2Vib3[gZYNmfHmuYYTpc44hd2ZiaHnzeI9v\SCKMzDheEBMOTh?	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJ7MkS5Nkc,OjF{OUK0PVI9N2F-
U937	NF3remRMcW6jc3WgRZN{[Xl?	NV\VNJpGPSEQvF2=	M4XWPFI1KGh?	MlTiSG1UVw>?	MVjJcohq[mm2aX;uJI9nKGirc4TvcoUh[WOndInseJJidnOoZYLhd4Uh[XO\|ZYPz[YQh[XNiaX7jdoVie2Vib3[gdIFvNWGlZYT5cIF1\WRiaHnzeI9v\SCKNDDs[ZZmdA>?	NYDZToRDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyPVI1QTJpPkKxNlkzPDl{PD;hQi=>
U937	MV;LbY5ie2ViQYPzZZk>	NYfJWHBKPSEQvF2=	NF3TW3EyPSCvaX6=	M3XBd2ROW09?	NILoXmlKdmirYnn0bY9vKG:oIHjpd5RwdmViYXPleJltfHKjboPm[ZJie2ViYYPz[ZN{\WRiYYOgbY5kemWjc3Wgc4YhcGm\|dH;u[UBJOyCjY3X0fYxifGmxbjDs[ZZmdA>?	MlHZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{OUK0PVIoRjJzMkmyOFkzRC:jPh?=
A2780	MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2LUbVk3KGh?	MUHEUXNQ	MYXJR\|UxRTFwNkKg{txO	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTZ\|NESzNEc,OjF4M{S0N\|A9N2F-
COLO205	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYG5OkBp	NXnOeFJvTE2VTx?=	MXrJR\|UxRTJwMUKg{txO	MnrjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF4M{S0N\|AoRjJzNkO0OFMxRC:jPh?=
Hep3B	M1i4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1W5NlQ5KGh?	NYrFO4Q2TE2VTx?=	MkfxS2k2OD1zLkKxJO69VQ>?	MkOzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5MUKxOFYoRjJzN{GyNVQ3RC:jPh?=
GM11272	NHTse41HfW6ldHnvckBCe3OjeR?=	NInNSHoyODBibl2=	M3nuUlczKGh?	Mnj3SG1UVw>?	NFvVb\|JT\WGldHn2ZZRqd25ib3[gUYVEeDJibYX0ZY51KGW6cILld5Nqd25iYYSgNVAhfG9iMUCwJI5O	Ml7IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6NEC3NVYoRjJzOESwO\|E3RC:jPh?=
CFBE41o	NU\QcmpSU2mwYYPlJGF{e2G7	M1:1XVUh\|ryP		M3fWfWROW09?	NIGydYpFd3ewIILl[5Vt[XSrb36gc4YhUESDQ{egZZQhOC5{IITvJFUhfU1?	NVz0SWM1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5PFQ6PThpPkKxPVg1QTV6PD;hQi=>
CFBE41o	NXjmcllsTnWwY4Tpc44hSXO\|YYm=	MXGxJO69VQ>?	NVW5UoloOjRiaB?=	NFK4OJJFVVOR	NYj0[FB3WmW\|dH;yZZRqd25ib3[gR2ZVWiCmZXz0ZWY2ODhibYX0ZY51KHS{YX\mbYNscW6pIITvJINmdGxic4Xy[oFk\SCjczDncJlkd2[xcn3z	M3G2SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUi0PVU5Lz5{MUm4OFk2QDxxYU6=
DU145	M4ry[2tqdmG\|ZTDBd5NigQ>?	MU[yMlUh\|ryP	Mmi3NlQhcA>?	MmPaSG1UVw>?	NHXGPZJKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNidYDy[Yd2dGG2aX;uJI9nKHB{MYfh[lEheHKxdHXpckBmgHC{ZYPzbY9v	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ4MEG2Okc,OjJ{NkCxOlY9N2F-
DU145	M3;zRmtqdmG\|ZTDBd5NigQ>?	NUjTfWtTPSEQvF2=	M{DyXlI1KGh?	MnnvSG1UVw>?	NYjlSYdzUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHjpd5RwdmViSESgZYNmfHmuYYTpc44>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ4MEG2Okc,OjJ{NkCxOlY9N2F-
DU145	MY\LbY5ie2ViQYPzZZk>	NGrMN3c2KM7:TR?=	MYOyOEBp	NV7HfZVWTE2VTx?=	Mof5TY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGirc4TvcoUhUDNiaInw[ZJi[2W2eXzheIlwdg>?	M3fWXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mk[wNVY3Lz5{MkK2NFE3PjxxYU6=
786-0	MlXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\0Ok4zKM7:TR?=	Mlu0O\|IhcA>?	M17WdWROW09?	MlvRS2k2OD1\|LkKg{txO	NX3xNXhqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0N\|U3PjlpPkKyOFM2PjZ7PD;hQi=>
A498	Mmm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVS2MlIh\|ryP	M1r5ZVczKGh?	NYHkNI9vTE2VTx?=	M1\XRmdKPTB;MT62JO69VQ>?	NIrKSno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSzOVY3QSd-MkK0N\|U3Pjl:L3G+
A549/ATCC	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13oblYvOiEQvF2=	MnTtO\|IhcA>?	NXL2SVR6TE2VTx?=	MXXHTVUxRTFwNjFOwG0>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR\|NU[2PUc,OjJ2M{W2Olk9N2F-
ACHN	NYTpbWd6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLCXo5FPi5{IN88US=>	MljSO\|IhcA>?	NUHuRphbTE2VTx?=	M4XVfGdKPTB;MT6zJO69VQ>?	MmXiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2M{W2OlkoRjJ{NEO1OlY6RC:jPh?=
BT549	Mmm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;J[lYvOiEQvF2=	NITSWZg4OiCq	MoD3SG1UVw>?	MWnHTVUxRTFwMzFOwG0>	NFi2bYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSzOVY3QSd-MkK0N\|U3Pjl:L3G+
EKVX	NV3YR5o2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYizbZVQPi5{IN88US=>	Mkf1O\|IhcA>?	Mm\MSG1UVw>?	MUPHTVUxRTFwMzFOwG0>	NUfPSGMxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0N\|U3PjlpPkKyOFM2PjZ7PD;hQi=>
HCT15	NYr2XlU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHu5NHc3NjJizszN	M4jqe\|czKGh?	M3PP[2ROW09?	M3TB[GdKPTB;Mj61JO69VQ>?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR\|NU[2PUc,OjJ2M{W2Olk9N2F-
HOP92	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjHXJU3NjJizszN	MkSxO\|IhcA>?	NW\M[nR5TE2VTx?=	M3\HUWdKPTB;NDFOwG0>	MnT2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2M{W2OlkoRjJ{NEO1OlY6RC:jPh?=
IGROV1	MlS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGfSZno3NjJizszN	NIPESYY4OiCq	NV;2clliTE2VTx?=	MWDHTVUxRTFwMzFOwG0>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR\|NU[2PUc,OjJ2M{W2Olk9N2F-
LOXIMVI	Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2W2TVYvOiEQvF2=	MVO3NkBp	NVixb25sTE2VTx?=	MkXhS2k2OD1zIN88US=>	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR\|NU[2PUc,OjJ2M{W2Olk9N2F-
M14	M2\uVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\rOm1xPi5{IN88US=>	M3Sx[\|czKGh?	NUS5WYxXTE2VTx?=	MUDHTVUxRTFwMzFOwG0>	M3TDSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEO1OlY6Lz5{MkSzOVY3QTxxYU6=
MALME-3M	MofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3K0N\|YvOiEQvF2=	NXvI[GxnPzJiaB?=	M4\XZ2ROW09?	M2XPWmdKPTB;MD6zNkDPxE1?	MnPQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2M{W2OlkoRjJ{NEO1OlY6RC:jPh?=
MCF10A	MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3PidVYvOiEQvF2=	NEXKTYg1QCCq	MoLxSG1UVw>?	M3HGO2dKPTB;OT62JO69VQ>?	M2\6SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEO1OlY6Lz5{MkSzOVY3QTxxYU6=
MDA-MB-435	MoK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XCXlYvOiEQvF2=	MUm3NkBp	NXvSO5dETE2VTx?=	MW\HTVUxRTBwNTFOwG0>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR\|NU[2PUc,OjJ2M{W2Olk9N2F-
MDA-MB-468	MnXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3P0NVYvOiEQvF2=	M3rjVVczKGh?	NYOybnE6TE2VTx?=	MkTvS2k2OD1yLk[zJO69VQ>?	NWLhNodtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0N\|U3PjlpPkKyOFM2PjZ7PD;hQi=>
MOLT4	Mn\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jLcVYvOiEQvF2=	M3HxcVczKGh?	M1rEVGROW09?	NUTSO45nT0l3ME2wMlQh\|ryP	MorXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2M{W2OlkoRjJ{NEO1OlY6RC:jPh?=
NCI-ADR-RES	NXfvXFFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTlOk4zKM7:TR?=	M{HhdlczKGh?	NHK5R3dFVVOR	MXfHTVUxRTBwMU[g{txO	NILX[oM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSzOVY3QSd-MkK0N\|U3Pjl:L3G+
NCI-H23	M1v6Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU[2MlIh\|ryP	NIjGepA4OiCq	Ml3HSG1UVw>?	NWLySopTT0l3ME2xJO69VQ>?	NHvoW5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSzOVY3QSd-MkK0N\|U3Pjl:L3G+
NCI-H322M	NGXDR3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlW0Ok4zKM7:TR?=	NH7BbZA4OiCq	MWTEUXNQ	MmLES2k2OD1yLke5JO69VQ>?	NF;o[HE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSzOVY3QSd-MkK0N\|U3Pjl:L3G+
NCI-H460	NFu5WnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\JOIMxPi5{IN88US=>	MYi3NkBp	M2rjc2ROW09?	M1XZTWdKPTB;MD63PUDPxE1?	MmS1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2M{W2OlkoRjJ{NEO1OlY6RC:jPh?=
NCI-H522	NET5TnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYG3WlI6Pi5{IN88US=>	NHrXT244OiCq	MmjCSG1UVw>?	MVzHTVUxRTBwNTFOwG0>	Mkf1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2M{W2OlkoRjJ{NEO1OlY6RC:jPh?=
OVCAR3	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV34bFN4Pi5{IN88US=>	M4jyOVczKGh?	MVXEUXNQ	MnnNS2k2OD1zLkOg{txO	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR\|NU[2PUc,OjJ2M{W2Olk9N2F-
OVCAR4	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWS2MlIh\|ryP	NFrW[Gg4OiCq	MlnWSG1UVw>?	NVy2[mVMT0l3ME20JO69VQ>?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR\|NU[2PUc,OjJ2M{W2Olk9N2F-
OVCAR5	MmDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGTmenE3NjJizszN	MneyO\|IhcA>?	M4TCfWROW09?	M2nZWGdKPTB;MD63PUDPxE1?	NVu1WlluRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0N\|U3PjlpPkKyOFM2PjZ7PD;hQi=>
OVCAR8	NUfmV4JLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PROVYvOiEQvF2=	NE\udIk4OiCq	MVfEUXNQ	NVrhbYtxT0l3ME2wMlUh\|ryP	MnzzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2M{W2OlkoRjJ{NEO1OlY6RC:jPh?=
RXF393	M1zvdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3S4Z\|YvOiEQvF2=	MnXVO\|IhcA>?	MlS5SG1UVw>?	M33leWdKPTB;MT6zJO69VQ>?	MoexQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2M{W2OlkoRjJ{NEO1OlY6RC:jPh?=
SF268	NUfkeI1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXy2MlIh\|ryP	NVW1eJdPPzJiaB?=	M{Hj[WROW09?	NEDaTI9IUTVyPUGuOkDPxE1?	M2PX[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEO1OlY6Lz5{MkSzOVY3QTxxYU6=
SF295	Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYm4VHpvPi5{IN88US=>	M4rQdlczKGh?	M1W0UGROW09?	M4DKV2dKPTB;MT62JO69VQ>?	M172cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEO1OlY6Lz5{MkSzOVY3QTxxYU6=
SF539	NHLMbG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV22MlIh\|ryP	NGTIcIY4OiCq	M3LGbGROW09?	MUnHTVUxRTJizszN	Mn7uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2M{W2OlkoRjJ{NEO1OlY6RC:jPh?=
SK-MEL-2	M2nFPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1v5b\|YvOiEQvF2=	M1i1blczKGh?	NUW2SW5QTE2VTx?=	MU\HTVUxRTFwMzFOwG0>	M4H0TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEO1OlY6Lz5{MkSzOVY3QTxxYU6=
SK-MEL-28	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWS2MlIh\|ryP	MnSxO\|IhcA>?	NUPiXHp[TE2VTx?=	NGrTTmdIUTVyPUGg{txO	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR\|NU[2PUc,OjJ2M{W2Olk9N2F-
SK-MEL-5	NHHaRWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HiR\|YvOiEQvF2=	MoXPO\|IhcA>?	MonnSG1UVw>?	MWnHTVUxRTBwNkOg{txO	NUnuNGI2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0N\|U3PjlpPkKyOFM2PjZ7PD;hQi=>
SKOV3	NVvBR2ZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUe2MlIh\|ryP	MX:3NkBp	NV;kfXQ{TE2VTx?=	NIH2[lZIUTVyPUGg{txO	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR\|NU[2PUc,OjJ2M{W2Olk9N2F-
SN12C	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVy2MlIh\|ryP	NXG0d4lQPzJiaB?=	NFr4cHhFVVOR	MnPzS2k2OD1{IN88US=>	Ml\5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2M{W2OlkoRjJ{NEO1OlY6RC:jPh?=
SNB19	NHPhOGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmKxOk4zKM7:TR?=	M2XzW\|czKGh?	NH3yZ\|FFVVOR	NVTRWVVGT0l3ME2wMlY{KM7:TR?=	MnHOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2M{W2OlkoRjJ{NEO1OlY6RC:jPh?=
SNB75	MkfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlf4Ok4zKM7:TR?=	MV:3NkBp	NWntbFJtTE2VTx?=	MonvS2k2OD1yLke5JO69VQ>?	NETEdFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSzOVY3QSd-MkK0N\|U3Pjl:L3G+
SR	MlnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7rOk4zKM7:TR?=	MmDoO\|IhcA>?	M1fLcWROW09?	NXjiTIdZT0l3ME2wMlQh\|ryP	M{P1RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEO1OlY6Lz5{MkSzOVY3QTxxYU6=
T47D	NHmzd4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;wdpI3NjJizszN	MkLZO\|IhcA>?	M{Hy[GROW09?	M4nOWWdKPTB;MD61JO69VQ>?	MnLEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2M{W2OlkoRjJ{NEO1OlY6RC:jPh?=
TK10	NEnsWnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfoeYQ3NjJizszN	NFWwUZI4OiCq	MXzEUXNQ	MWHHTVUxRTBwNkOg{txO	MkflQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2M{W2OlkoRjJ{NEO1OlY6RC:jPh?=
UACC257	NUHLeXZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYO2MlIh\|ryP	NVzlNFJKPzJiaB?=	MYDEUXNQ	MoG5S2k2OD1yLkWg{txO	MkfJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2M{W2OlkoRjJ{NEO1OlY6RC:jPh?=
UACC62	NEX2[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXG2MlIh\|ryP	NYLvc2pbPzJiaB?=	M{XkUmROW09?	NGPh[XRIUTVyPUCuOEDPxE1?	NEKwfJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSzOVY3QSd-MkK0N\|U3Pjl:L3G+
UO31	M3S1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoDjOk4zKM7:TR?=	MnHvO\|IhcA>?	M4Tse2ROW09?	M4nYNWdKPTB;MD61JO69VQ>?	M3jCc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEO1OlY6Lz5{MkSzOVY3QTxxYU6=
Hep3B	NGK4Oo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFq0XFE1QCCq	MnXiSG1UVw>?	NXSxNIJQT0l3ME2wMlY6KM7:TR?=	Mki1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2M{m4OlMoRjJ{NEO5PFY{RC:jPh?=
BE(2)-C	M{XxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4S1S\|czKGh?	MlXxSG1UVw>?	NIDZSW1KSzdyPUKg{txO	NH;3epc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkmzNlMyPid-MkK5N\|I{OTZ:L3G+
Bel7402	M4DqfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVq3NkBp	MlPxSG1UVw>?	MUHHTVkxRTF5IN88US=>	NInPRVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C2NVM4Pid-MkOwOlE{PzZ:L3G+
Bel7404	NYTjZ45MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWru[opDPzJiaB?=	NFrLeFFFVVOR	NH\0TnRIUTlyPUG4JO69VQ>?	MmfrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkGzO\|YoRjJ\|ME[xN\|c3RC:jPh?=
BGC823	NWDM[FA2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUW3NkBp	MX\EUXNQ	NGO1NllIUTlyPUeuOUDPxE1?	NHH0bJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C2NVM4Pid-MkOwOlE{PzZ:L3G+
MGC803	M3LLS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnjtO\|IhcA>?	MmP4SG1UVw>?	MXTHTVkxRTFyLkig{txO	M325V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|ME[xN\|c3Lz5{M{C2NVM4PjxxYU6=
SGC7901	NFywTW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWe3NkBp	MUDEUXNQ	NIjLWJlIUTlyPUmuOEDPxE1?	NIThPFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C2NVM4Pid-MkOwOlE{PzZ:L3G+
SKHEP1	NVnydFcxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MU[3NkBp	NV\XWWF6TE2VTx?=	NELtXHJIUTlyPUG3JO69VQ>?	M{i2NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|ME[xN\|c3Lz5{M{C2NVM4PjxxYU6=
SMMC7721	M3Hiemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWX2T3RPPzJiaB?=	M{n2Z2ROW09?	NI[0SpBIUTlyPUKwJO69VQ>?	NU\3NnhSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOlE{PzZpPkKzNFYyOzd4PD;hQi=>
NUGC3	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVWxNEDPxE1?			MnPSS2k:Oi57NDFOwG0>	NXHiZYV4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxOlM{OzJpPkKzNVY{OzN{PD;hQi=>
A2780 CisR	MlnnT4lv[XOnIFHzd4F6		NYGyWmZsOThiaB?=		MYnJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNESg{txO	MkT2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NUK2NFMoRjJ\|MkWyOlA{RC:jPh?=
CAL27 sens	NYq4ZWI6U2mwYYPlJGF{e2G7		NGO5UG8yQCCq		NVzVVXhPUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlM3KM7:TR?=	NXThT4pwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyOVI3ODNpPkKzNlUzPjB\|PD;hQi=>
CAL27 CisR	Mn7wT4lv[XOnIFHzd4F6		MljRNVghcA>?		MknLTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLk[xJO69VQ>?	NFfIVIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K1NlYxOyd-MkOyOVI3ODN:L3G+
KYSE-510 CisR	NHPWWZBMcW6jc3WgRZN{[Xl?		M3H1c\|E5KGh?		NXnX[lBGUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlU6KM7:TR?=	M2P4elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkWyOlA{Lz5{M{K1NlYxOzxxYU6=
KYSE-510 sens	NHrFUGNMcW6jc3WgRZN{[Xl?		NFT6bHYyQCCq		NYrCdZg5UW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlch\|ryP	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ3Mk[wN{c,OjN{NUK2NFM9N2F-
MDA-MB-231 sens	MVrLbY5ie2ViQYPzZZk>		M{DubFE5KGh?		MkjZTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLk[xJO69VQ>?	M{\QSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkWyOlA{Lz5{M{K1NlYxOzxxYU6=
MDA-MB-231 CisR	MY\LbY5ie2ViQYPzZZk>		MVWxPEBp		MnXtTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLk[xJO69VQ>?	M4LHN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkWyOlA{Lz5{M{K1NlYxOzxxYU6=
ES2	MlTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVi5b4tbPDhiaB?=	Ml7ESG1UVw>?	M4LDUmlEPTB;MUKuO{DPxE1?	NIradVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S5N\|Q1QSd-MkO0PVM1PDl:L3G+
MDA-MB-231	M2TJOGtqdmG\|ZTDBd5NigQ>?	NI\oO3EyOCEQvF2=	M1Tpc\|MxKG2rbh?=	MnfnSG1UVw>?	MmH5TY5pcWKrdHnvckBw\iCKRFHDNoE>	MmK2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUO0OFkoRjJ\|NEmzOFQ6RC:jPh?=
MDA-MB-231	NFfzO2FMcW6jc3WgRZN{[Xl?	M37wcVEh\|ryP	NFfkPJczPCCq	MXnEUXNQ	NEe3SJpKdmirYnn0bY9vKG:oIFjERWM3KGG\|c3Xzd4VlKGG\|IHHj[ZR6dGG2aX;uJIxmfmWuczDv[kB1fWK3bHnu	MnL0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUO0OFkoRjJ\|NEmzOFQ6RC:jPh?=
HS68	NHPhOphEgXSxdH;4bYMhSXO\|YYm=	NF20VW8yOCEQvF2=	M2XsSVczKGh?	MnnCSG1UVw>?	MorUTWM2OD12Lk[g{txO	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV5MEW0Nkc,OjN3N{C1OFI9N2F-
MEF	NGX3ZWtEgXSxdH;4bYMhSXO\|YYm=	MVGxNEDPxE1?	MUm3NkBp	MYPEUXNQ	MW\JR\|UxRTRwNDFOwG0>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV5MEW0Nkc,OjN3N{C1OFI9N2F-
BGC823	MoLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXnEUXNQ	NFPzNoZIUTVyPUOuNFkh\|ryP	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZyMUewOkc,OjN4MEG3NFY9N2F-
High5	NW\rRo5xU2mwYYPlJGF{e2G7		M{jEN\|I1KGh?		NGjYVoZKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IFjERWM3KHerdHigTWM2OCCxZjCwMlA6KM7:TR?=	M4joZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkCyOVI{Lz5{M{[wNlUzOzxxYU6=
High5	MXzLbY5ie2ViQYPzZZk>		M3PBR\|I1KGh?		NFK2dmVKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IFjERWMyKHerdHigTWM2OCCxZjCwMlEzKM7:TR?=	M1f5WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkCyOVI{Lz5{M{[wNlUzOzxxYU6=
High5	NVL1WodkU2mwYYPlJGF{e2G7		NXvrU2E4OjRiaB?=		NXHudndzUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDISGFEOyC5aYToJGlEPTBib3[gNE4yPyEQvF2=	NF\1PVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[wNlUzOyd-MkO2NFI2OjN:L3G+
A549	Mm[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M320NmROW09?	MWXJR\|UxRTFwMEe5JO69VQ>?	M2[3[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkS0NlExLz5{M{[0OFIyODxxYU6=
HCT116	Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NXTrNmxxTE2VTx?=	NWPSeXlHUUN3ME2wMlc2PyEQvF2=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ2NEKxNEc,OjN4NESyNVA9N2F-
K562	NHvaSGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NV;EWVlNTE2VTx?=	NID4XWpKSzVyPUCuOlQ2KM7:TR?=	NEm5U5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[0OFIyOCd-MkO2OFQzOTB:L3G+
GBC-SD	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\vZYw2KM7:TR?=	M3f4TVczKGh?	M1z2O2ROW09?	NELH[VZKSzVyPUG0Mlgh\|ryP	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzdyN{K2NEc,OjN5MEeyOlA9N2F-
HGC27	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml21OUDPxE1?	MWm3NkBp	NYnSb2lOTE2VTx?=	NH73OJZKSzVyPUWuOEDPxE1?	M3ywXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{C3NlYxLz5{M{ewO\|I3ODxxYU6=
HL60	NGGz[YJMcW6jc3WgRZN{[Xl?	NIPkTW82KM7:TR?=	NFu5N3czPCCq	M3\he2ROW09?	M2n6dWlvcGmkaYTpc44hd2ZiSFTBRy=>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzdyN{K2NEc,OjN5MEeyOlA9N2F-
Vero	M3\CR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3K1blczKGh?	MVjEUXNQ	MVvJR\|UxRTBwOTFOwG0>	MmXDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5OE[0OVIoRjJ\|N{i2OFUzRC:jPh?=
NCI60	NVnTSpZqS3m2b4TvfIlkKEG\|c3H5		NXLYSFBHPDhiaB?=	M4KxRWROW09?	MkjCS2k:OC53MzFOwG0>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDBzNUOyO{c,OjRyMUWzNlc9N2F-
SW620	NYHjNIpWS3m2b4TvfIlkKEG\|c3H5		MV20PEBp	NIS1VVJFVVOR	M1fWXGdKRTBwNUSg{txO	NIDpNGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECxOVMzPyd-MkSwNVU{Ojd:L3G+
U251	NICxXIJEgXSxdH;4bYMhSXO\|YYm=		NUe4OoxPPDhiaB?=	NVv0ZYRiTE2VTx?=	NULDOnNTT0l;MT61N{DPxE1?	NUDDVHJ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNVU{OjdpPkK0NFE2OzJ5PD;hQi=>
KM12	NVvSO4lZS3m2b4TvfIlkKEG\|c3H5		MmXSOFghcA>?	MkXtSG1UVw>?	NX\MPIVTT0l;MT64PEDPxE1?	NX;BSGpkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNVU{OjdpPkK0NFE2OzJ5PD;hQi=>
Hs578T	Mm\CR5l1d3SxeHnjJGF{e2G7		MYW0PEBp	NEPsWpdFVVOR	M1OxTGdKRTRwOEOg{txO	M4fSS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEG1N\|I4Lz5{NECxOVMzPzxxYU6=
MDA-MB-231	NUDtW\|l3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUO0PEBp		MV3JR\|UxRTBwMU[g{txO	NXuyV5U5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVUxOTZpPkK0NFk2ODF4PD;hQi=>
MCF7	NVrFWGo4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NV\hVZdyPDhiaB?=		MmqxS2k:OC52NTFOwG0>	NXPQeGh{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxNVk2PTVpPkK0NVE6PTV3PD;hQi=>
MDA-MB-435	M4naV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NH7Jc4k1QCCq		MnLxS2k:OC56ODFOwG0>	MnmxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMUm1OVUoRjJ2MUG5OVU2RC:jPh?=
AsPC1	Mn\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1ryRlMxKM7:TR?=	M3SwblQ5KGh?	MWjEUXNQ	Mon4TWM2OD1\|Lk[2JO69VQ>?	NGGwVm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG4OVM4QCd-MkSxPFU{Pzh:L3G+
Jurkat E6.1	MYrLbY5ie2ViQYPzZZk>		MnrZNkBp	M3nrdmROW09?	NEHsXoRKdmirYnn0bY9vKG:oIFjERWM1KHerdHigTWM2OCCxZjCwMlA1KM7:TR?=	NITiTpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK2NVg3Oid-MkSyOlE5PjJ:L3G+
KG1	NIrjU4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{L5WVQ5KGh?		MlTtTWM2OD1zLkG1JO69VQ>?	NFz6UXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWyOVAxOyd-MkS1NlUxODN:L3G+
HEL	NFnvWpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnvsOFghcA>?	NYSwO3RbTE2VTx?=	NFXaWG1KSzVyPUCuOFkh\|ryP	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ7NEC1OUc,OjR4OUSwOVU9N2F-
HSC3	MkTNR5l1d3SxeHnjJGF{e2G7		M{nVfFEzKGh?	MoDVSG1UVw>?	NX\w[VZYUUN3ME2wMlcyKM7:TR?=	M{DWe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{[2OVYxLz5{NEe2OlU3ODxxYU6=
HT-29	NH;6b4hEgXSxdH;4bYMhSXO\|YYm=		NInTcm8yOiCq	MXXEUXNQ	MofSTWM2OD1yLkeyJO69VQ>?	Ml;DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5Nk[1OlAoRjJ2N{[2OVYxRC:jPh?=
KB	MUXDfZRwfG:6aXOgRZN{[Xl?		MYGxNkBp	NHfNfZJFVVOR	MoXGTWM2OD1yLke1JO69VQ>?	M1fle\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{[2OVYxLz5{NEe2OlU3ODxxYU6=
H460	NUTEZYpzS3m2b4TvfIlkKEG\|c3H5		M4\kVlEzKGh?	NF;kWoxFVVOR	NEKwPZdKSzVyPUCuPFIh\|ryP	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd4NkW2NEc,OjR5Nk[1OlA9N2F-
MONE1	MWfDfZRwfG:6aXOgRZN{[Xl?		NHzLepgyOiCq	NHrhPVNFVVOR	MlHmTWM2OD1zLkG4JO69VQ>?	NH3KbYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe2OlU3OCd-MkS3OlY2PjB:L3G+
MKN45	M{WzWGN6fG:2b4jpZ{BCe3OjeR?=		NGr4cokyOiCq	M2nTe2ROW09?	NGXjVlVKSzVyPUGuNlUh\|ryP	NHf5cIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe2OlU3OCd-MkS3OlY2PjB:L3G+
TSGH	M1HzZmN6fG:2b4jpZ{BCe3OjeR?=		NVraRXBtOTJiaB?=	NVfCdZdZTE2VTx?=	NFywWmlKSzVyPUKuNFkh\|ryP	NVHLfINLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OlY2PjBpPkK0O\|Y3PTZyPD;hQi=>
HL60	MlH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NX6wfXdEPzJiaB?=	NGjqVINFVVOR	MX3HTVUxRTBwOUOg{txO	NXrlb2d3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA2ODBpPkK0PVAxPTByPD;hQi=>
HEK293	NHyxe\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoCzO\|IhcA>?	M33xcGROW09?	NF3QWFdIUTVyPUGzJO69VQ>?	NG[1WHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFUxOCd-MkS5NFA2ODB:L3G+
Jurkat	NH3jW21EgXSxdH;4bYMhSXO\|YYm=	NHWxTWcyODBizszN	NHi2TZQ4OiCq		MW\HTVUxRTBwOTFOwG0>	Mki1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC3OFMoRjJ2OUCwO\|Q{RC:jPh?=
GM15850	M37LfWtqdmG\|ZTDBd5NigQ>?	Mkj6Nk42KM7:TR?=	NGC3R246PiCq	M4SzV2ROW09?	NHyzd5Zld2W\|IH7veEBqdmirYnn0JGhFSUNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm\|dH;u[UBJOyCueYPpcoUhOTRiYXPleJlt[XSrb36gc4YhTliQIHflcoU>	MkDHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ7MkGzOlcoRjF4OUKxN\|Y4RC:jPh?=
GM15850	NU[3TpM{U2mwYYPlJGF{e2G7	M1HCeFIvPSEQvF2=	MlnHPVYhcA>?	M3vpeWROW09?	Mn\O[I9meyCwb4SgbY5pcWKrdDDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFUh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	NWjZVW9mRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[5NlE{PjdpPkG2PVIyOzZ5PD;hQi=>
GM15850	MWTLbY5ie2ViQYPzZZk>	NUnvPIdxOi53IN88US=>	NV3PW5BxQTZiaB?=	MoS0SG1UVw>?	NILqWmxld2W\|IH7veEBqdmirYnn0JGhFSUNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm\|dH;u[UBJPCCueYPpcoUhOTJiYXPleJlt[XSrb36gc4YhTliQIHflcoU>	NH3lcJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkmyNVM3Pyd-MU[5NlE{Pjd:L3G+
GM15850	NV7DbG5IU2mwYYPlJGF{e2G7	Mn;sNk42KM7:TR?=	M3\YSVk3KGh?	NHrEOmVFVVOR	Mnf5[I9meyCwb4SgbY5pcWKrdDDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm\|aX7lJFkh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	M3;0RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OUKxN\|Y4Lz5zNkmyNVM3PzxxYU6=
GM15850	M3G1SGtqdmG\|ZTDBd5NigQ>?	NEC4T3YzNjVizszN	M2PKbFk3KGh?	NUjzVYxMTE2VTx?=	MWXkc4V{KG6xdDDpcohq[mm2IFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgPEBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?=	NVrKb2dwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[5NlE{PjdpPkG2PVIyOzZ5PD;hQi=>
GM15850	NHfzTnJMcW6jc3WgRZN{[Xl?	MYeyMlUh\|ryP	MUS5OkBp	MknCSG1UVw>?	NHf3UZBld2W\|IH7veEBqdmirYnn0JGhFSUNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm\|dH;u[UBJPCCueYPpcoUhOTZiYXPleJlt[XSrb36gc4YhTliQIHflcoU>	M1T6eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OUKxN\|Y4Lz5zNkmyNVM3PzxxYU6=
GM15850	NHzCXXZHfW6ldHnvckBCe3OjeR?=	MWO1JO69VQ>?	NGDtR\|YyOiCq	MnfDSG1UVw>?	MVzoZZMhdm9iZX\m[YN1KG:wIF\YUkBuWk6DIHX4dJJme3Orb36=	M{PjbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OUKxN\|Y4Lz5zNkmyNVM3PzxxYU6=
U937	M1HofWtqdmG\|ZTDBd5NigQ>?	M2\PZVUh\|ryP	NEP2dnczPCCq	M4K4XGROW09?	MVroZZMhdm9iZX\m[YN1KG:wIHHsdIhiKHS3YoXsbY4h[WOndInsZZRqd25?	M2LiOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NES3O\|UxLz5zN{S0O\|c2ODxxYU6=
U937	NYLEV5kyU2mwYYPlJGF{e2G7	MoK1NUDPxE1?	M2K1W\|I1KGh?	MnvjSG1UVw>?	M{my[YhieyCwbzDl[oZm[3Rib36gZYxxcGFidIXieYxqdiCjY3X0fYxifGmxbh?=	NEPDc489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{S0O\|c2OCd-MUe0OFc4PTB:L3G+
PANC1	NV7Ifo1HTnWwY4Tpc44hSXO\|YYm=	NGrSeGwyKM7:TR?=	NFXLOVAzPCCq		MVrkc4V{KG6xdDDpcoNz\WG\|ZTDpckBxOjetaYCxJIdmdmViZYjwdoV{e2mxbh?=	M{[5dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUi4O\|Q1Lz5zN{W4PFc1PDxxYU6=
PANC1	NVLPbm5UTnWwY4Tpc44hSXO\|YYm=	MkTmNUDPxE1?	M1ywZlQ5KCCq		NXP5fphY\G:nczDuc5QhcW6lcnXhd4UhcW5icEK3b4lxOSCpZX7lJIV5eHKnc4Ppc44>	MoPpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3OEi3OFQoRjF5NUi4O\|Q1RC:jPh?=
Caco-2	MXnGeY5kfGmxbjDBd5NigQ>?	NFzObWo2KM7:TR?=	MWGyOEBp	NEDCXJVFVVOR	MmG4[I9meyCwb4SgbY5lfWOnIGCyNXdCTjFiZ3Xu[UBmgHC{ZYPzbY9v	NHXoXXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0N\|g1OCd-MkCxOFM5PDB:L3G+
SCC4	NGXHXWdHfW6ldHnvckBCe3OjeR?=	MnPUNUDPxE1?	MUexNEBucW5?	MlvFSG1UVw>?	NHzPSoJp[XNibn:gZYdwdmm\|dDDhZ5Rqfmm2eTDheEBXTFJiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKEO\UEK0JIdmdmViZYjwdoV{e2mxbh?=	NEfJOXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MES1NlIzPSd-MkC0OVIzOjV:L3G+
A549	M3PkXWZ2dmO2aX;uJGF{e2G7	MofEOUDPxE1?	MXWzJIg>	MlvLSG1UVw>?	MkLo[I9meyCwb4SgbY5lfWOnIHH1eI9xcGGpeTDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCOQ{PJTS=>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh3NUKwPEc,OjB6NUWyNFg9N2F-
HCT116	M2DGdGtqdmG\|ZTDBd5NigQ>?	NHfkO2cxNjNizszN	MV6zNEBp	M1O3XmROW09?	NGLTb\|Fld2W\|IH7veEBqdmirYnn0JGhFSUNzIHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iCqaYP0c45mKEh\|S{mgZYNmfHmuYYTpc44>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB6ME[0O{c,OjFyOEC2OFc9N2F-
HepG2	MmrySpVv[3Srb36gRZN{[Xl?	MlLTNVAh\|ryP	NHrSeJozPCCq	MmXaSG1UVw>?	MkL0[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{BpgXCncnHj[ZR6dGG2aX;uJI9nKHB3Mx?=	NGLJVII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUW0PFU5Oid-MkG1OFg2QDJ:L3G+
GM11272	MnL6SpVv[3Srb36gRZN{[Xl?	MlzlNE4yKM7:TR?=	M4HtSFczKGh?	NWP4dGZOTE2VTx?=	MWXkc4V{KG6xdDDy[YFkfGm4YYTlJG1mS3B{IH31eIFvfCCneIDy[ZN{cW:w	Mm[2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6NEC3NVYoRjJzOESwO\|E3RC:jPh?=
MDA-MB-231	M3roPGtqdmG\|ZTDBd5NigQ>?	NVPvXWhJOTBizszN	M{jSRVUhdWmw	MmLPSG1UVw>?	NFf5UXdld2W\|IH7veEBqdmirYnn0JGhFSUN{YR?=	NFjwRoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S5N\|Q1QSd-MkO0PVM1PDl:L3G+
MDA-MB-231	MYHLbY5ie2ViQYPzZZk>	M{LjV\|Eh\|ryP	MWKyOEBp	NITEcYRFVVOR	M{iyR4Rw\XNibn;0JIlvcGmkaYSgTGRCSzZiYYPz[ZN{\WRiYYOgZYNmfHmuYYTpc44hdGW4ZXzzJI9nKHS3YoXsbY4>	NWS4bJU1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVM1PDlpPkKzOFk{PDR7PD;hQi=>
K562	NIfr[3pMcW6jc3WgRZN{[Xl?				M3TZbYRw\XNibn;0JIlvcGmkaYSgTGRCSw>?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV7MUGxNUc,OjN3OUGxNVE9N2F-
Jurkat	MUfDfZRwfG:6aXOgRZN{[Xl?	NXzpdHlkOjBizszN	NV\hd3JjPzJiaB?=	NVX0UVViTE2VTx?=	NV3RNY1Rdm9iY4n0c5RwgGmlaYT5JIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9v	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDNyNEO0PEc,OjR\|MESzOFg9N2F-
HCT116	NEfXbXJCeG:ydH;zbZMhSXO\|YYm=	MX6zJO69VQ>?	NHrENVAzPCCq	MXvEUXNQ	Ml;n[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCyNUOgdJJwfGWrbjDs[ZZmdA>?	M2LBVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{[2OVYxLz5{NEe2OlU3ODxxYU6=
KASUMI-1	NFXXOXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTl7LkG3JI5O	M1HRR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
KARPAS-45	M1zYPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfxS5ZKSzVyPUG3N{45QSCwTR?=	MkDSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
BHT-101	M1HiNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTJ2ND6xPEBvVQ>?	NI\jTow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
H9	NVe1XZNvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHSTWM2OD1{NUWuNFQhdk1?	MlTLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
PA-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIH0SlNKSzVyPUK4Ok4zPiCwTR?=	Mlf3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
NEC8	NHLwTZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkH3TWM2OD1{OEmuN\|ghdk1?	NIrhVFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
MHH-PREB-1	MnfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3zTWM2OD1{OUSuOVMhdk1?	NH61TVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
NB7	NHnDPHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnVNlNFUUN3ME2zOFUvPzRibl2=	NIfqb4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
A3-KAW	MknUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mom3TWM2OD12MECuOVkhdk1?	NV;NSZg{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
NB69	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHzoR2lKSzVyPUSxNU44OSCwTR?=	MlK0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
EoL-1-cell	M1rqVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoDuTWM2OD12NUSyOUBvVQ>?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
CHP-212	NXGzNm9VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XsTGlEPTB;NEW3MlU{KG6P	MmH5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
C2BBe1	MkDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkDyTWM2OD12N{KuNVkhdk1?	NWPRTVJPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
697	NFnXZnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlLNTWM2OD12N{OuOFEhdk1?	MnXPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
BCPAP	MlL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPvb4JSUUN3ME21NFEvPDJibl2=	NWnsXoxHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
L-363	NV3YNGo5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWqwcXdNUUN3ME21NFMvOSCwTR?=	NWSxfXJrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
ES8	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{TER2lEPTB;NUKzMlU{KG6P	M2XLc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
BE-13	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTV{Nj65OkBvVQ>?	NEHPZ4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
CTB-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTV\|Nz65NkBvVQ>?	Mmj0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
HD-MY-Z	MoO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTV\|OD6xN{BvVQ>?	NFfLbpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
NKM-1	NIXoc3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTV2ND6yO{BvVQ>?	NXPxUJQ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
NCI-H720	MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1TiZWlEPTB;NU[wMlE5KG6P	NHXpZYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
KY821	NXLPU3M1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MonhTWM2OD13NkOuNlUhdk1?	M1PMZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
OVCAR-5	MoXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\BcZZKSzVyPUW3Ok4yOSCwTR?=	M4nGdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
CTV-1	NW\aVHZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;YdmlEPTB;NUixMlU3KG6P	NYD0[VZ7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
P12-ICHIKAWA	NUnHO21VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLCbYVKSzVyPUW5Ok42OSCwTR?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
DB	MortS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHrJdIRKSzVyPUW5PE42PyCwTR?=	NH;mSmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
CHL-1	M2P6Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4nvXWlEPTB;NkSyMlA5KG6P	M4P4PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
A4-Fuk	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2DkNmlEPTB;NkS0MlkyKG6P	M3v2fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
MV-4-11	NV7HNW11T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTZ3OT6xJI5O	NFXnPWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
RPMI-8226	M3XhZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn;wTWM2OD14N{iuNVghdk1?	M{Do[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
NB14	NVnnVm9LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\PbWlEPTB;Nkm2Mlk2KG6P	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
DOHH-2	NVW2NXdrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlP2TWM2OD15ME[uOlghdk1?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
D-423MG	NHT4Z3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2XINGlEPTB;N{C2Mlg6KG6P	M{HPNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
D-283MED	NWTqcGpXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoC5TWM2OD15MUSuNVQhdk1?	NUHn[IJkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
ES1	M2C1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rUOGlEPTB;N{K0MlQhdk1?	Ml61QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
GOTO	NWfIW4tzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;FTWM2OD15MkmuNVIhdk1?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
NCI-H209	NEnF[lRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULtUmg3UUN3ME23NlkvQSCwTR?=	MniwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
MOLT-13	NHzmSJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1vPe2lEPTB;N{O4Mlk5KG6P	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
ATN-1	MoTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYO4[483UUN3ME23OFAvOjhibl2=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
DU-4475	NETIfGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEO3UpFKSzVyPUe1NU46OSCwTR?=	M{na[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
NB10	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvseHZ{UUN3ME23OVEvQTJibl2=	M1PyPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
KG-1	NInjc3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTd5NT60OUBvVQ>?	NX3qTmx7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
MOLT-4	MoTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTd6Nz60OkBvVQ>?	NH\peJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
TE-1	NVz4bHBMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1LVNGlEPTB;N{mxMlEhdk1?	MoTwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
SBC-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml3qTWM2OD15OUOuPFQhdk1?	MoDsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
HEL	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3nqbGlEPTB;OEC2MlA5KG6P	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
SK-MEL-2	NGrUPHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRThyOT60OEBvVQ>?	NYrEUGx6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
KU812	M4DMRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRThzMz6xJI5O	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
RPMI-8866	MlviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HmeGlEPTB;OEGzMlY4KG6P	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
ALL-PO	Mki3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlOxTWM2OD16MUSuOlYhdk1?	MofSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
LU-139	NWLuWJFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX7UOHMxUUN3ME24NlIvQDZibl2=	NVj2NoplRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
RS4-11	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGj2bIJKSzVyPUizNk41PSCwTR?=	M2TnN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
EW-18	NG[2NZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NED2SlFKSzVyPUizNk46PiCwTR?=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
P30-OHK	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3PvZmlEPTB;OEO1Mlchdk1?	NVnCcIp6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
D-566MG	M3zGdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\KUGFuUUN3ME24N\|gvPjJibl2=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
HSC-4	NWK5VIE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXqVZlkUUN3ME24OFYvPTFibl2=	NV:ySnB3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
QIMR-WIL	NH63VWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVLqfY1jUUN3ME24OlIvODNibl2=	Mn;DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
SW954	MnTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIXpSoxKSzVyPUi2N{4yPiCwTR?=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
HGC-27	MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MonQTWM2OD16N{KuN\|Qhdk1?	M4jyVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
HH	NWnCcW1qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXvcopKSzVyPUi5OE4yOiCwTR?=	NUTke5RjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
KE-37	M2\xcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLiTWM2OD16OUSuOlIhdk1?	M2HnN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
SK-N-DZ	M{m1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLZTWM2OD17MECuOFMhdk1?	MlnyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
J-RT3-T3-5	NIPVOnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV3xd\|hGUUN3ME25NVAvPDlibl2=	MlTqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
A427	MkTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTl{MD64OEBvVQ>?	NUPZeFhiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
ECC10	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1nBT2lEPTB;OUS1Mlg4KG6P	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
EW-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHiTWM2OD17NEeuNlYhdk1?	M1raOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
MIA-PaCa-2	M4DN[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTl2OT6xNkBvVQ>?	NFqyUXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
HCC2218	NXW4[\|J3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTl3OD60PEBvVQ>?	MofhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
HAL-01	NV3mUlhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\mOI5KSzVyPUm2PE4xPCCwTR?=	M{e1XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
RD	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTl5ND60OUBvVQ>?	Mn3oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
SK-N-AS	NFPvXoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFThS4lKSzVyPUm4PE4yKG6P	NVPBZnFXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
ML-2	NV[1XFg3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrWUZNMUUN3ME2xMlAxPDB5IN88US=>	NGCxUJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
MEL-HO	M2nPV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnPWTWM2OD1zLkCwOVgzKM7:TR?=	MofrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
MS-1	NFzBbFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTFwMEC2NVch\|ryP	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
NCI-SNU-1	Ml\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTFwMEKzN\|Eh\|ryP	NYH1eJZIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
8505C	NYTPO\|I4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XxT2lEPTB;MT6wNlM{OSEQvF2=	M1qxblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
MN-60	MoXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTFwMEK2PEDPxE1?	NYHwdpJzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
SAS	NFH4bphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jXTmlEPTB;MT6wOFA5OSEQvF2=	NFTHPZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
EFM-19	NFfYVHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4n4U2lEPTB;MT6wOFg4QSEQvF2=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
Ca9-22	MnLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;SZYJKSzVyPUGuNFUyODdizszN	M1;zfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
NBsusSR	NVXPU3RCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlP5TWM2OD1zLkC1NVY3KM7:TR?=	NXrEN\|I{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
NB13	M3\aTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYrOZ4pyUUN3ME2xMlA2PTBzIN88US=>	NYHlWmkzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
SF295	M4LIUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDGPG5KSzVyPUGuNFY3OjRizszN	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
U-2-OS	M1r1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7BTWM2OD1zLkC3PVEyKM7:TR?=	M4TYdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
NCI-H526	NIj4ZoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYjjUmFsUUN3ME2xMlA5OjlzIN88US=>	NF;rOpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
KMOE-2	NH\0V5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NETpVIlKSzVyPUGuNFk1OjJizszN	Mn;aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
RCM-1	NIi5O41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2fM[GlEPTB;MT6xNlExOiEQvF2=	M{S0fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
MC116	NHXHe4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MljETWM2OD1zLkGzOlIyKM7:TR?=	M1exblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
NCI-H1092	NHTWfYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7nTWM2OD1zLkG1OFA3KM7:TR?=	MoPUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
EW-3	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MljvTWM2OD1zLkG3NlEzKM7:TR?=	NWDuNFN5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
HCT-116	Mn\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmT0TWM2OD1zLkG3O\|Uh\|ryP	M33sbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
MC-IXC	NGj0UYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTFwMUe4PFEh\|ryP	MlHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
LB1047-RCC	M37YZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU\wcmhlUUN3ME2xMlE5OzF{IN88US=>	M2G3b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
VM-CUB-1	NV[0fodyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MonWTWM2OD1zLkG5NVA5KM7:TR?=	NGC1VXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
NB5	MmDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlTlTWM2OD1zLkG5PFU3KM7:TR?=	M2X2TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
SKG-IIIa	NYTpepBkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW[0TW16UUN3ME2xMlI{PDZ2IN88US=>	Mo\MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
HO-1-N-1	NHKzV2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmD1TWM2OD1zLkKzPFM2KM7:TR?=	NVXIb\|Z{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
EFO-27	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHxTWM2OD1zLkK1NFQ{KM7:TR?=	M17YelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
MHH-NB-11	MkexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEDrU\|dKSzVyPUGuNlg{OjlizszN	NWflXYtjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
SW620	NGq3S5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHrJcIFKSzVyPUGuNlkxOThizszN	MlnMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
MOLT-16	NUTyOnc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3rmdWlEPTB;MT6yPVc6PyEQvF2=	NEHH[IQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
NTERA-S-cl-D1	M2e2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIDTUpZKSzVyPUGuN\|E4PjFizszN	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
VA-ES-BJ	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVHHW3JTUUN3ME2xMlMzPDd5IN88US=>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
HCC1419	M2jzOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7zdHBKSzVyPUGuN\|QxOjdizszN	MkPjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
NCI-H69	NVLQRodJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmr5TWM2OD1zLkO0NVEzKM7:TR?=	NHfybVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
DEL	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEDxXFZKSzVyPUGuN\|UyPjJizszN	MmO1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
LXF-289	M1TESmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnniTWM2OD1zLkO1NlQh\|ryP	M4XHOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
EW-11	MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF64V2FKSzVyPUGuN\|YxOjZizszN	NUfrXHg6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
KP-4	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVy1NolEUUN3ME2xMlM4ODh3IN88US=>	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
NOS-1	NHj4R2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTFwNEGxPVQh\|ryP	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
SK-NEP-1	NFrTVFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTFwNEG2PVMh\|ryP	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
LAMA-84	MkjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\QZ2lEPTB;MT60N\|k1PSEQvF2=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
ES5	M1m3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTFwNESzJO69VQ>?	NVKyNmM3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
HuO9	MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTFwNEWzOlIh\|ryP	NWC5SpRvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
COLO-684	NYS1NoRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTFwNE[xNVgh\|ryP	MoK2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
EW-24	MnPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXroR3BFUUN3ME2xMlQ3PTNzIN88US=>	NHrBSlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
BV-173	NU\FR5pFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn7nTWM2OD1zLkS3NlkyKM7:TR?=	MoX6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
NCI-H1770	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTFwNEi1N\|Yh\|ryP	MlrNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
HuP-T4	NFvnU5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTFwNEmzJO69VQ>?	NV[wOlRXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
TYK-nu	M3z6TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFq5XXhKSzVyPUGuOFk5PTFizszN	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
YH-13	NYXOXGE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NED4NphKSzVyPUGuOFk5QTRizszN	M1\lNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
H4	M2XMSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzpd\|hbUUN3ME2xMlUxQTF{IN88US=>	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
OVCAR-8	NX3MO5A3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVT3VINFUUN3ME2xMlU1PDd5IN88US=>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
NCI-H23	Moi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTFwNUS2OFUh\|ryP	NV;XXYM1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
ES7	MmDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{ixcmlEPTB;MT61OFc4OyEQvF2=	NYrzbFYzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
COR-L88	Ml3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7WTWM2OD1zLkW2OFI1KM7:TR?=	M{DQSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
TI-73	NUTEemgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1Ls[WlEPTB;MT61PVA3KM7:TR?=	NVjDfoN5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
RT-112	NILyPI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjlTWM2OD1zLkW5Nlg1KM7:TR?=	NWHtUlVPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
HuO-3N1	NGfPfJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTFwNUmzPFUh\|ryP	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
HC-1	Mki5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XQV2lEPTB;MT61PVg3PiEQvF2=	M{XpWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
HT55	NFfyR\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWD1SmFrUUN3ME2xMlY2OTNzIN88US=>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
IA-LM	NEe4VIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1XwT2lEPTB;MT62PVI4QCEQvF2=	NGXMRXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
EM-2	M2T2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTFwN{CwNVQh\|ryP	M{fYTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
MHH-ES-1	NXX6SpZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mly4TWM2OD1zLkewOFM2KM7:TR?=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
CAL-27	NFvqe\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYrI[VRvUUN3ME2xMlcxPjJzIN88US=>	NGHO[lY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
COLO-800	NVjzd5hmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XkTWlEPTB;MT63NVE4QSEQvF2=	NYPEbXNURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
HCE-T	M3G1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zSRWlEPTB;MT63NVUh\|ryP	NIfvOHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
CAMA-1	MlLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3VTWM2OD1zLkexPVcyKM7:TR?=	M{\GWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
LOXIMVI	NHX3PYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{C0Z2lEPTB;MT63NlEyKM7:TR?=	NVru[2lnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
NH-12	NV\Xe\|VPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn3XTWM2OD1zLkeyOlkyKM7:TR?=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
TCCSUP	M1;CdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTFwN{K4Nlkh\|ryP	NIPnZWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
MDA-MB-361	MlLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFi2OVVKSzVyPUGuO\|MyPTdizszN	NYqxenZGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
EW-16	Mm\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUHCcGV[UUN3ME2xMlc1OTB5IN88US=>	NWXHdWRkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
SNU-423	MnvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlrMTWM2OD1zLke1PFI4KM7:TR?=	NXnkZnpWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
Daoy	NIm3O5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHradpdKSzVyPUGuO\|Y{OTlizszN	NXLmVHdURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
ES4	NF3ifXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIfaPYpKSzVyPUGuO\|g4PDFizszN	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
PFSK-1	NF3udFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\CcGlEPTB;MT64NFM4KM7:TR?=	M4j4NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
ES3	MkmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{PLXWlEPTB;MT64NlY5OSEQvF2=	MlPpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
ONS-76	M3\GfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTFwOEK4PVch\|ryP	NXfkN\|ZrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
JVM-3	NYW2bohFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYPJR\|UxRTFwOEW0OVEh\|ryP	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
OS-RC-2	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4TseWlEPTB;MT64O\|E2OSEQvF2=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
COLO-320-HSR	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTnO2JCUUN3ME2xMlg5OTl5IN88US=>	NUnCS2VPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
HN	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTFwOEi3NlUh\|ryP	NULOWYE1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
HT	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTFwOEi5OFch\|ryP	NEfBdmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
LoVo	NYLjeGhwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2f5SGlEPTB;MT64PVgyKM7:TR?=	NWroPY9oRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
CGTH-W-1	NV7jdYp7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTFwOEm5OFYh\|ryP	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
NB6	M3i2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{nzVWlEPTB;MT65NVI6QCEQvF2=	NVXVWopERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
EW-22	MnPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGHSU5VKSzVyPUGuPVI5QDdizszN	NHTPcGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
ES6	M4mx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1P0SGlEPTB;MT65N\|Y{OSEQvF2=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
SCC-15	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\OfZNQUUN3ME2xMlk{QDF7IN88US=>	NVjRelBuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
HL-60	NH65XFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTFwOUO5NFIh\|ryP	MkK1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
human HOP-92	MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTFwOUSwOlUh\|ryP	NFHvN2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
SW626	MmPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTFwOUS4PVkh\|ryP	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
HEC-1	NHy0ZphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPLfnZKSzVyPUGuPVU{PiEQvF2=	NIH5NGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
LB2241-RCC	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTFwOUiyN\|Eh\|ryP	NEPUV3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
Ramos-2G6-4C10	MnnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2iw[GlEPTB;MT65PVQ6OyEQvF2=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
A101D	NGSzRpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTJwMkCzNFMh\|ryP	M3vnS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
NCI-H446	NX2yd\|dHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk[3TWM2OD1{LkC0OVk6KM7:TR?=	NEDkfWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
SBC-5	MlnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYe0UmhGUUN3ME2yMlA3OTR5IN88US=>	NG\M[5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
HOS	NXTJSXM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmTnTWM2OD1{LkC3OlU{KM7:TR?=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
K5	NXn3VVVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlSxTWM2OD1{LkC3PFEyKM7:TR?=	M2j3XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
HLE	M4G3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M160OWlEPTB;Mj6wPFUzQSEQvF2=	NILYfVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
HSC-2	NWnld5E4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzL[IRKSzVyPUKuNVI5QThizszN	NXHDXI5HRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
LCLC-97TM1	M3qzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGmzXZVKSzVyPUKuNVQ2QDNizszN	MnnDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
DMS-273	Mni0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTJwMUS4N\|ch\|ryP	M2\KTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
TE-8	NVTTNXh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEK0fG1KSzVyPUKuNVU4PjVizszN	MnLxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
DSH1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH3reHRKSzVyPUKuNVY{QThizszN	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
CAL-51	NEHoeolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHmwb4pKSzVyPUKuNVY3QTlizszN	M4X3ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
IST-SL1	NUG2WYU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfYR3hIUUN3ME2yMlE3QDR2IN88US=>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
GCT	NV:ydZN7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTJwMUe3O{DPxE1?	M1[5TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
SW948	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTJwMUi0OVYh\|ryP	M3vMe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
NOMO-1	M2PYXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTJwMUmzNVch\|ryP	NUjWRnNbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
C8166	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYmxd\|lYUUN3ME2yMlIyOzN2IN88US=>	NF\pUpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
OC-314	MoHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NELDWGVKSzVyPUKuNlMzPTlizszN	NWHlcmd4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
CAL-39	NIjHNoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGD4XpFKSzVyPUKuNlM3OjZizszN	NIO4TpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
MDA-MB-453	MkDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEi0SW9KSzVyPUKuNlQzPzVizszN	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
A673	MlPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{HUdGlEPTB;Mj6yOVg3OiEQvF2=	NFjmcZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
HTC-C3	NVPyPVNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTJwMk[4OUDPxE1?	MnjyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
NCI-H1666	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17lc2lEPTB;Mj6yPFEyOSEQvF2=	NXrX[WI5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
PSN1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3;SWmlEPTB;Mj6yPFkyOyEQvF2=	M4myZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
GI-1	M3voUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlO1TWM2OD1{LkOwOVQ{KM7:TR?=	NYHuS4c2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
HuH-7	NFjSRYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXrIZmVMUUN3ME2yMlMxPjN5IN88US=>	MmfoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
JAR	MnHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWHrPXJjUUN3ME2yMlMyQTh5IN88US=>	NGj0SmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
5637	M4fUVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{izT2lEPTB;Mj6zNlEzQSEQvF2=	MonaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
GB-1	M1f1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFm0SYRKSzVyPUKuN\|I{OzVizszN	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
KP-N-YS	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHWxcIFKSzVyPUKuN\|I3OTVizszN	M3jGU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
OAW-42	NULDbYZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTJwM{O0NVYh\|ryP	NHLsXZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
8-MG-BA	MkW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLNWpBKSzVyPUKuN\|M6ODZizszN	MmPLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
RH-18	Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmnCTWM2OD1{LkO1NFIzKM7:TR?=	NUnST2RqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
NCI-H1155	NGDKd2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFn6dpJKSzVyPUKuN\|Y4OjVizszN	MnG5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
NB17	MomwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfEfFBKSzVyPUKuN\|gzPDNizszN	M1zFR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
NCI-H1437	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTJwNEG4O\|Mh\|ryP	MlnrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
SN12C	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDTTWM2OD1{LkSzNlE1KM7:TR?=	M2PKOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
HSC-3	M{nmfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTJwNES1NFkh\|ryP	M1q3XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
GAMG	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEm3dWlKSzVyPUKuOFQ2PjFizszN	NHP1UY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
HT-1080	M1TRTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIDhRVJKSzVyPUKuOFQ5PjRizszN	Ml\VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
A549	NUjWRZZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFLFNotKSzVyPUKuOFQ5QTNizszN	NYS0[5ZMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
KNS-62	NWLPNWJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmLXTWM2OD1{LkS1NFYyKM7:TR?=	NHna[nA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
YKG-1	M3vKbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmTlTWM2OD1{LkS1OFM4KM7:TR?=	NFfXfFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
LU-134-A	M1rFcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rQfmlEPTB;Mj60O\|AxQCEQvF2=	NITnPYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
FADU	NHruepBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\4c2lEPTB;Mj60O\|E3OiEQvF2=	NHfhR2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
TGBC11TKB	NYXCRo5WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHWS\|BKSzVyPUKuOFcyPzdizszN	NIPjVlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
HT-3	MmG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUjSV5pmUUN3ME2yMlQ6PTN3IN88US=>	MoPRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
NCI-H2170	MmXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHS5NopKSzVyPUKuOVA2PDlizszN	NFW5bok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
Mo-T	MoHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3MTWM2OD1{LkWwPVI4KM7:TR?=	NUDNRXM4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
CCRF-CEM	NGCwdZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTJwNUOwOFMh\|ryP	MkHuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
KU-19-19	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\CO5duUUN3ME2yMlU{PTF\|IN88US=>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
NCI-H1048	MnO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2GzTGlEPTB;Mj61OVAzPSEQvF2=	NVP4c25zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
KOSC-2	NYS1c2J6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NInxRpdKSzVyPUKuOVYxPzZizszN	NXm1em9PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
A431	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{j3[mlEPTB;Mj61OlM{PSEQvF2=	M4TLPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
COR-L23	NFfN[nRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7IVWZlUUN3ME2yMlU5PTZ4IN88US=>	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
MKN28	NVHGSmZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTJwNUmwN\|ch\|ryP	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
22RV1	M1PV[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmrJTWM2OD1{LkW5Nlc1KM7:TR?=	Ml\5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
ABC-1	MlLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnEVpNUUUN3ME2yMlYxPDZizszN	NWrtVplDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
NCI-H2126	M36wbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVX6bohCUUN3ME2yMlYxQTh2IN88US=>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
DoTc2-4510	MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\kd\|VKSzVyPUKuOlIyQDVizszN	NIPn[GY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
SCC-4	NWDLW2IyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTJwNkOwNVIh\|ryP	NWrnTHFPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
NCI-H661	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGrvO4dKSzVyPUKuOlQxQDVizszN	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
RPMI-2650	NYDxVmpqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn7RTWM2OD1{Lk[0NVQ{KM7:TR?=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
NCI-H510A	NWPNOnB4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTJwNkS0NlYh\|ryP	Mn;LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
BPH-1	M2LrRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\0fIxKSzVyPUKuOlU5PSEQvF2=	NFG4Xnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
M14	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVHweVJ2UUN3ME2yMlY3QTl\|IN88US=>	MoHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
G-402	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHzTWM2OD1{LkewOFUyKM7:TR?=	NF;kcIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
AsPC-1	NUDJcoR7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTJwN{GxO{DPxE1?	NVjERnByRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
NB12	Ml\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4X5cGlEPTB;Mj63NVcyKM7:TR?=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
SK-HEP-1	M3LD[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1[1UmlEPTB;Mj63OFM6OSEQvF2=	MofmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
U-266	NGLMbolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTJwN{exNlEh\|ryP	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
AM-38	NYrUNGp[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTJwN{ezOVUh\|ryP	NE\LXmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
PC-14	NX;QUm1DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTJwOEC1NUDPxE1?	NXPhXYVFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
EGI-1	M4TzWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jGfmlEPTB;Mj64NVc1OyEQvF2=	NWLUcWtvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
LS-411N	NHHaellIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnT0TWM2OD1{LkiyN\|Mh\|ryP	MnjFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
BFTC-905	M4LR[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1THZ2lEPTB;Mj64OVUzOyEQvF2=	NH34OlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
CaR-1	M3\pT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3j5dGlEPTB;Mj64OkDPxE1?	NEHZTJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
NCI-H292	M3fZRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULxVG1bUUN3ME2yMlg3PTl4IN88US=>	NH3TNGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
8305C	NX;hblNOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnncZRuUUN3ME2yMlg3PjR3IN88US=>	NV23U2hbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
SNU-449	M4nyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTJwOEmxPFIh\|ryP	NVjWdnJ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
LCLC-103H	NVzmc5JJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{jpTWlEPTB;Mj65NFQ{QCEQvF2=	NX7VSm97RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
SW1573	NEPQUmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULSZXVOUUN3ME2yMlk3ODh{IN88US=>	NFq5VpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
MLMA	NX7GdnE6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NES5SYVKSzVyPUKuPVY4OTdizszN	NGfoc3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
NCI-H1355	NHr6dYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml:5TWM2OD1\|LkCwO\|k3KM7:TR?=	MkfHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
RMG-I	NYDqeFFGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLTWG5KSzVyPUOuNFI2QTJizszN	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
BB65-RCC	NYnrOmh1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTNwMEOzNVQh\|ryP	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
PC-3	MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTNwMEO4O\|Qh\|ryP	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
SF268	M3e1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV25d4tGUUN3ME2zMlA1PTJ\|IN88US=>	M2HPcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
NCI-H810	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIrwXWRKSzVyPUOuNFQ5OjNizszN	MmjrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
MEG-01	NETDOHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHyTWM2OD1\|LkC2NVY1KM7:TR?=	NICxUlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
SW13	M2rkUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHqyPZNKSzVyPUOuNFc5PDdizszN	M3jTPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
RH-1	NWHlboxQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3zIRWlEPTB;Mz6xNFI4QCEQvF2=	NWnLUotYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
GT3TKB	M1TvbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTNwMUGyPFMh\|ryP	NWPJeo9{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
TK10	NXT2XGtXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPWXnJKSzVyPUOuNVM4OjRizszN	NXXJS25sRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
T-24	NE\PV2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTNwMUWwO{DPxE1?	M4LOPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
A498	NIX1So1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHzJellKSzVyPUOuNlA5PzFizszN	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
GR-ST	NUXrdHJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGrpVWVKSzVyPUOuNlIyOzlizszN	MkWwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
LB2518-MEL	NUH3NGpxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NULnV5V5UUN3ME2zMlIzOzl6IN88US=>	M4T5TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
T47D	MoThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYe4e5JxUUN3ME2zMlI{PjJ5IN88US=>	Ml7vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
NCI-H1651	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NETCVo5KSzVyPUOuNlQ3PDRizszN	NXf4OIVZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
EC-GI-10	NEj0fpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTNwMk[xOVMh\|ryP	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
HT-29	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXaW\|dKSzVyPUOuNlY3OTRizszN	NIDabXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
GI-ME-N	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTNwMkm1NVEh\|ryP	NXT0XHZtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
SW756	Mkj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrXfJgyUUN3ME2zMlI6PjJ7IN88US=>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
RKO	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTNwM{C3OVch\|ryP	M4PHTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
NCI-H1563	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\3OXZKSzVyPUOuN\|MxOThizszN	MmmzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
DJM-1	NUfCfXVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DBNmlEPTB;Mz6zO\|Y4PCEQvF2=	NVPvfIdMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
L-428	NHHoSWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHS1WHpKSzVyPUOuOFAxPDVizszN	NV\aSZJ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
NCI-H2122	M{SxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEC4WIhKSzVyPUOuOFE{OTJizszN	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
Ca-Ski	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofqTWM2OD1\|LkS1OFMh\|ryP	MmHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
639-V	NXnO[mFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3LmWWlEPTB;Mz60OlA2PyEQvF2=	NV[yOJNuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
SW1116	NXHaTHFvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3m4bGlEPTB;Mz60OlI3QSEQvF2=	NGrReJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
DMS-114	NYXQUVNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYL6W3VXUUN3ME2zMlQ4ODZ4IN88US=>	NH;jc5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
MZ2-MEL	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4m4RWlEPTB;Mz60O\|Y5OSEQvF2=	NHLYc5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
COLO-829	M2\S[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{jjVWlEPTB;Mz61NFA4OyEQvF2=	M1XDe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
J82	NFK4ZW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYKzSZFkUUN3ME2zMlUxPTdizszN	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
EW-13	M4W4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXsc\|Q3UUN3ME2zMlUzPTFizszN	NVHhTXRIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
RXF393	MmrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NETsToZKSzVyPUOuOVMzQTRizszN	NXjsN2MzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
CAL-62	NH20R4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\TTWM2OD1\|LkW0OVE1KM7:TR?=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
OCUB-M	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoOwTWM2OD1\|LkW0OlY2KM7:TR?=	MkjIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
BT-474	NEnEc5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3rkbGlEPTB;Mz62N\|MyKM7:TR?=	NFXrdpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
KYSE-180	NYjRWHlJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmfITWM2OD1\|Lk[zN\|czKM7:TR?=	NEjRdpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
NCI-H650	MnPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;ETWM2OD1\|Lk[0Nlg4KM7:TR?=	NH\ubZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
Detroit562	NUHl[m9yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4n4W2lEPTB;Mz62OVAzOiEQvF2=	Mm\1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
SW48	M1jqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFztd\|ZKSzVyPUOuOlU3PTdizszN	NXXUWFdjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
KYSE-450	MnSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{K1W2lEPTB;Mz62PFU5OiEQvF2=	Mo\kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
KYSE-510	NEPLfpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTNwN{KxPFEh\|ryP	M4XBWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
GP5d	MoDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTNwN{K5OUDPxE1?	M37vU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
RPMI-7951	M2m0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITo[HVKSzVyPUOuO\|Q4OjNizszN	NGHDTIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
Becker	NGHr[4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH7vTZdKSzVyPUOuO\|UxOTJizszN	M4PRPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
WM-115	NIDvRmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXTXopKSzVyPUOuO\|gyQTVizszN	Ml;1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
G-401	NVOyXodvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIj5bmZKSzVyPUOuO\|kxQDVizszN	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
PANC-08-13	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTNwN{m2NFIh\|ryP	MnyyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
SW982	NHvDNm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoHCTWM2OD1\|LkiwOVUyKM7:TR?=	NXjHdY9bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
D-263MG	NXrFTpg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHSyd\|FKSzVyPUOuPFIxPTFizszN	M37R[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
KM-H2	M{\UOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzIOoNqUUN3ME2zMlgzPjJ2IN88US=>	M17NU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
SK-MEL-3	MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\W[4FSUUN3ME2zMlgzQDRzIN88US=>	NXjmW3ZuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
NCI-H1581	NWn4eVBTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUO3bldmUUN3ME2zMlg1PDh6IN88US=>	NWT5Z2J3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
LS-123	NETzOpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTNwOEe5NFkh\|ryP	MlXRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
CAKI-1	NFfXelZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXrxPJNVUUN3ME2zMlg6ODV{IN88US=>	NW\CfYJPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
MEL-JUSO	M4fiRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\0R5dKSzVyPUOuPFkyPTNizszN	NEfqUWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
HCE-4	Mn\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{HuW2lEPTB;Mz65NVY3OyEQvF2=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
TE-10	MkLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTNwOUKwNUDPxE1?	MlrSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
OVCAR-4	NWrkSJhsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVWySZJpUUN3ME2zMlkzQDh7IN88US=>	M{fhbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
ETK-1	M1fMPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4fGWGlEPTB;Mz65OFY{PSEQvF2=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
A2780	NXr2ZmRoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MorFTWM2OD12LkC1PVY3KM7:TR?=	MmfqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
LU-65	NHXuSoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGTMZWZKSzVyPUSuNFc3OzNizszN	MkmzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
BHY	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1nLVGlEPTB;ND6xNlQ6PSEQvF2=	M{jNT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
COR-L105	Mn;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TLWGlEPTB;ND6xN\|A2OSEQvF2=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
CAL-12T	NEnFc3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTRwMUOxNFMh\|ryP	NEX2bnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
SCH	NGjiV3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MojDTWM2OD12LkG1O\|Q{KM7:TR?=	M1rJVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
CW-2	NE[1OmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\YV2lEPTB;ND6xPVAxOSEQvF2=	M{XMclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
HCC1806	MnvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmTJTWM2OD12LkKwN\|EzKM7:TR?=	NXvRfpJpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
KP-N-YN	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrXNGhKSzVyPUSuNlA6OjdizszN	MoPlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
T98G	NXrVXoIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2W2S2lEPTB;ND6yNlE2PyEQvF2=	NXn0[WRQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
CAL-54	M4jaSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLaTWM2OD12LkKyN\|gyKM7:TR?=	NXzXWG9YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
CAL-33	NIf2XGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml\STWM2OD12LkKzNFY1KM7:TR?=	MmLMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
SNU-C2B	M2fPeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3PW[WlEPTB;ND6yOFc3QSEQvF2=	Mk\PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
NUGC-3	M4fCOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTRwMkW1NFUh\|ryP	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
DOK	MnyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHPjPZlKSzVyPUSuNlY2QTNizszN	NGjPcno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
MMAC-SF	NHzURlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTRwMk[4OVkh\|ryP	NETQSVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
KYSE-70	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXXL[XFTUUN3ME20MlI6OzRizszN	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
A204	MojHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{fC[2lEPTB;ND6zOVgxOyEQvF2=	M3X1OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
SCC-25	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mor1TWM2OD12LkO1PFE6KM7:TR?=	NEnDN489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
EPLC-272H	MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DNNWlEPTB;ND6zPFk2KM7:TR?=	M2nyNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
CAL-120	NEewWJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mom2TWM2OD12LkO4PVkzKM7:TR?=	MlP6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
LS-513	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlPhTWM2OD12LkSyNVk5KM7:TR?=	NWDVe3FJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
CAPAN-1	M4LsfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnqUpg3UUN3ME20MlQzOzh{IN88US=>	MofJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
ESS-1	NX;YPG1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\LeWwzUUN3ME20MlQzPzJ2IN88US=>	M1:2NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
GMS-10	NIXx[YNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4mxPWlEPTB;ND60NlgyQSEQvF2=	NYjRPXZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
NCI-N87	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnLrTWM2OD12LkWwPFY5KM7:TR?=	NH;BdIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
HMV-II	M2rMRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWL3enVSUUN3ME20MlUyPzNizszN	Mk\wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
COLO-741	NVfZfGRpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;WU2tKSzVyPUSuOVU6QTRizszN	MmLqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
MKN45	M4Pk[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLob2NKSzVyPUSuOVc4OzJizszN	NUPuNHhZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
OAW-28	NIDxeG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rVUWlEPTB;ND61PFM6QCEQvF2=	M{PMNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
OCI-AML2	NELCfXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2TKe2lEPTB;ND62OVI{QCEQvF2=	M4jIO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
MDA-MB-231	NU\XSmR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\1V5RJUUN3ME20MlcxOjR\|IN88US=>	M{[wNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
NCI-H1648	NHrUZXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn3VTWM2OD12LkeyNlc{KM7:TR?=	NV3RbG1vRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
NCI-H1792	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUG0UGNPUUN3ME20Mlc3OTB5IN88US=>	NHLzW3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
GCIY	NIXTWlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2DXcmlEPTB;ND63O\|QzPCEQvF2=	NF:2UFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
Hs-578-T	NXvKenNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXibo83UUN3ME20Mlc4PjV3IN88US=>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
SW962	NXvSUJVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDjTWM2OD12Lke4NFEyKM7:TR?=	M4PrVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
NCI-H630	MmG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTRwN{iwPFEh\|ryP	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
786-0	NWPaT\|FbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\KUGlEPTB;ND63PFc4OyEQvF2=	NF7UPJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
FTC-133	MoXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTRwN{myOlMh\|ryP	NISxTY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
BT-20	NYHXS2FXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1TiXWlEPTB;ND63PVQzQSEQvF2=	M{fjUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
Mewo	NIDhWmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkTmTWM2OD12LkixO\|Q4KM7:TR?=	MonZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
SW780	NVThXm81T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vQ[mlEPTB;ND64OVc3PiEQvF2=	M4r2NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
OE33	NWPwRZFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2nEWmlEPTB;ND64O\|cyOyEQvF2=	M1v6O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
HCC1569	Mon6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHjmN5dKSzVyPUSuPFg1PThizszN	NF\kUZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
TE-6	MkTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTRwOUO5O\|ch\|ryP	NHGx[2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
SK-N-FI	M3zVUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTRwOUS0NlEh\|ryP	NIGzcVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
PANC-03-27	Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVjFO\|c3UUN3ME20Mlk6QTZ{IN88US=>	NIX2NJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
MCF7	M1HHdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnfXTWM2OD13LkCwO\|M5KM7:TR?=	MmnCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
UACC-257	M3u2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVT1N3RzUUN3ME21MlAzQDR3IN88US=>	MnXIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
SW1088	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2jzR2lEPTB;NT6wNlk1PCEQvF2=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
A704	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTVwMEOwOkDPxE1?	NFn0PFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
A2058	NGL2PHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTVwMEW5NFgh\|ryP	Mm[2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
Calu-3	NY\jN2E6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfscWNKSzVyPUWuNFY1PTJizszN	NHfHWXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
RERF-LC-MS	MkTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYDYcW1ZUUN3ME21MlA3QTB\|IN88US=>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
AU565	NUWwcJpJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTVwMEm3NFIh\|ryP	NIT0O449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
DMS-79	NHTk[pRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTVwMUO4PFMh\|ryP	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
DK-MG	NIOxXHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1fwTGlEPTB;NT6xPFQ{QCEQvF2=	NHPPZlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
HuCCT1	M2PCfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlH6TWM2OD13LkKzPFU3KM7:TR?=	Mk\yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
HT-144	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4K5PGlEPTB;NT6yOFk5PyEQvF2=	NGLCXoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
M059J	NGSyVotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTVwMkW3OkDPxE1?	NIX0VYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
COLO-792	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnnlTWM2OD13LkK2N\|U3KM7:TR?=	M4nES\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
SF539	M{e4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1PteWlEPTB;NT6yOlY{OiEQvF2=	NX7xNZRzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
SK-UT-1	MoTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTVwMke3OVEh\|ryP	NVTjTlV3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
NCI-H1703	NUX0SnZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XRcWlEPTB;NT6zOVgzPiEQvF2=	NYDnNWplRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
SW837	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4LCV2lEPTB;NT6zO\|g4QCEQvF2=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
U251	NHnwOmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTVwM{mwPVYh\|ryP	Ml;RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
SW1710	M3TDZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXK2PGFzUUN3ME21MlQyPTV2IN88US=>	Mn\3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
NCI-H1299	NYjLOJo3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTVwNE[zN\|Uh\|ryP	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
RVH-421	MkXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoHNTWM2OD13LkS5PVA5KM7:TR?=	NImzUXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
UM-UC-3	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzMRYpnUUN3ME21MlYzPjVzIN88US=>	NWrJcZJ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
MDA-MB-175-VII	MmHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLqZZRKSzVyPUWuOlQxPDFizszN	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
KYSE-270	NXnhTo5kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3XxemlEPTB;NT62OlA{OSEQvF2=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
COLO-668	NUfoWGs5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDYTWM2OD13LkexN\|Ih\|ryP	NYX5eZJORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
LN-405	MkHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkjkTWM2OD13LkezNFg2KM7:TR?=	MoO4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
HT-1376	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{T5bmlEPTB;NT63PFA2OiEQvF2=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
769-P	NV\XfIZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TyN2lEPTB;NT64OlcyQCEQvF2=	NF;UUVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
HuP-T3	NFnkUIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NES3clhKSzVyPUWuPFg3PzdizszN	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
MDA-MB-415	MnTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTVwOUKxN\|kh\|ryP	NWTHPWtTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
MKN7	MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmr2TWM2OD13Lkm4PEDPxE1?	M{myTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
KS-1	MofBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fvb2lEPTB;NT65PFg{PiEQvF2=	M3vJUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
647-V	M4\5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPiTlk3UUN3ME21Mlk6OTR6IN88US=>	M3LtWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
COLO-679	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTZwMECyOVUh\|ryP	NUHmVHVlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
AN3-CA	M1;QZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUTxNHJyUUN3ME22MlA{PDRzIN88US=>	NV;JV3p{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
C32	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTZwMUOwN\|Qh\|ryP	M{\WcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
KM12	NUjuOVU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIe2fHFKSzVyPU[uNlQxQTlizszN	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
KINGS-1	NEfOOIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zlTmlEPTB;Nj6yOlE2OiEQvF2=	NEXDVGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
KYSE-410	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFfSc\|hKSzVyPU[uN\|A3PDVizszN	NFvZVpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
HPAF-II	NIm1dYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGi4eJZKSzVyPU[uN\|U1QCEQvF2=	NHvRTWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
LAN-6	M2XybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrBPW9KSzVyPU[uOFk3OzFizszN	M37RPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
LU-99A	M4jGW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTZwNUW5PFkh\|ryP	NUThOmsxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
SJSA-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnBTWM2OD14LkW2N\|Q4KM7:TR?=	M1e0TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
MSTO-211H	M4LKW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnPvTWM2OD14LkeyNlM{KM7:TR?=	NIGzc4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
SW900	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFHNcIRKSzVyPU[uO\|YzOjFizszN	M{GzfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
LNCaP-Clone-FGC	NWPXRXJFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvofZVKSzVyPU[uPFA1ODNizszN	NWX4T5VTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
OMC-1	MkjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYPOelhWUUN3ME22Mlg2PDB{IN88US=>	NYjybmszRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
IST-MEL1	NIP6PWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlvLTWM2OD14Lki5OlY6KM7:TR?=	NVTwflJCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
TE-9	NF62UIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTZwOEm4OFch\|ryP	M1vwVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
NCI-H2030	MmO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIS4eYhKSzVyPU[uPVEzOjZizszN	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
BFTC-909	MnPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTqXmZ2UUN3ME23MlAxPjRzIN88US=>	M4LF[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
NCI-SNU-5	M{Twbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2HvTWlEPTB;Nz6wNlE2QSEQvF2=	NInle\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
TE-5	M2\mO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjyOZlKSzVyPUeuNFI5QDFizszN	MljUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
SK-MES-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\YUWlEPTB;Nz6wOVQzPyEQvF2=	NWjwV3dKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
SHP-77	M2D6UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mlz2TWM2OD15LkGzPVUzKM7:TR?=	NVnYTW1uRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
NCI-H1623	NGOwXoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnz5TWM2OD15LkG0NFczKM7:TR?=	NVThWItjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
TE-11	NFXhVINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTdwMUWxPFQh\|ryP	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
EKVX	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnPqTWM2OD15LkG5NlY4KM7:TR?=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
OVCAR-3	NX;wdmx[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3XJZWlEPTB;Nz6yNVE{OyEQvF2=	M{XrT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
C3A	NUTqeHpET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTdwM{S1NkDPxE1?	NG\BXVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
CFPAC-1	MlvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVrOOXlFUUN3ME23MlM3OjJ{IN88US=>	MkLNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
MG-63	M2npRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTdwNEG4OFkh\|ryP	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
KYSE-140	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoXjTWM2OD15LkS0NFYyKM7:TR?=	M{SxOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
MPP-89	NYn3PHkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGPkTHVKSzVyPUeuOVk4OjlizszN	MlS3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
COLO-824	NGn5T\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTPTWM2OD15LkeyPFY{KM7:TR?=	NUT1PYhxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
SiHa	NETq[JVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlzWTWM2OD15LkizO\|A4KM7:TR?=	NXXYRWhJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
SNU-387	MlTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXYcoxKSzVyPUeuPFU{PDdizszN	NIDZPHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
A172	MoTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrSS\|NKSzVyPUeuPFYyPzJizszN	NWLMTHR4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
COLO-680N	M1jlT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTdwOUG3N{DPxE1?	NVzzSFVYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
HCC1395	NYjXNo5vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRThwMEW0OVIh\|ryP	NHrrfVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
NCI-H28	MoTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XTNGlEPTB;OD6wOVk3OyEQvF2=	NInOe249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
LC-2-ad	M{\GW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2DFN2lEPTB;OD6yNVk{PyEQvF2=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
S-117	NGnYOlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1P4SWlEPTB;OD6yOVM2OyEQvF2=	NG\od4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
NCI-H1838	NWnS[oR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEG2U\|FKSzVyPUiuNlU4QDFizszN	M3rkdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
PANC-10-05	NU\SU28yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4TuemlEPTB;OD6zO\|A1PyEQvF2=	NGPwV\|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
KALS-1	Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnPOTWM2OD16LkWwPVI5KM7:TR?=	NHfYNHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
LS-1034	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlPtTWM2OD16LkW3OFM4KM7:TR?=	NXnWc41JRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
TGBC1TKB	M{T0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRThwN{O1N\|Uh\|ryP	NHXKWGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
OE19	M33ES2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXTnTVJUUUN3ME24Mlc3OjZ{IN88US=>	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
D-502MG	NHHpVndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1HzemlEPTB;OD63Olk6PCEQvF2=	MoX5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
JEG-3	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRThwN{i2NVgh\|ryP	Mm\pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
DBTRG-05MG	M1fsd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{PnXGlEPTB;OD64O\|U3PSEQvF2=	MlTDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
ME-180	MnPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTlwME[3NlUh\|ryP	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
NCI-H1573	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTlwMUC1N\|Ih\|ryP	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
HCC2998	NXHDflJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUD4S29GUUN3ME25MlE{PjhzIN88US=>	NInwe5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
ACHN	NX3ISIpTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrCTWM2OD17LkK0PVc2KM7:TR?=	NVTiOYdTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
D-392MG	MkPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rENGlEPTB;OT6yOVcyPSEQvF2=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
no-11	NELvOnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk\STWM2OD17LkK2NFI5KM7:TR?=	M4rhU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
KLE	NHr5cVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2Lrd2lEPTB;OT6zNlI{OiEQvF2=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
Calu-6	MmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHZbWRjUUN3ME25MlM4PTJ6IN88US=>	MmPDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
LB831-BLC	NVfJN\|hDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\VS\|F[UUN3ME25MlQ2OTdzIN88US=>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
SW684	NWPVbJFkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXlTWM2OD17LkS2NVE3KM7:TR?=	NGrHZos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
SH-4	NWDOfIZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHTTI5KSzVyPUmuOFk{PjRizszN	MmXRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
IST-MES1	M{P1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTlwNUG2OFQh\|ryP	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
Saos-2	NVLsUGdrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVqxU2FsUUN3ME25MlUzOTl3IN88US=>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
NCI-H2087	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFHIVGpKSzVyPUmuOlc{PTJizszN	NHi3RXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
SCC-9	MoK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTlwN{G4NVYh\|ryP	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
MFE-280	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXlTIpvUUN3ME25MlczPzh3IN88US=>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
BEN	NX\GfoFtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIf5emRKSzVyPUmuPFIyPTlizszN	MnLGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
CP50-MEL-B	M3XIb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIexdmdKSzVyPUmuPVI1OzJizszN	MmfQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
SK-MEL-28	NFrLZXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmm2TWM2OD1zMD6wNVk{KM7:TR?=	NU[4UlFFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
NCI-H2452	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTFyLkG2JO69VQ>?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
NCI-H1395	M3v5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmH4TWM2OD1zMD6xO\|gh\|ryP	NGmwVHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
NCI-H2052	Mn\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTFyLkG4PFIh\|ryP	NFW2RoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
A375	M2fzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW[yTYtHUUN3ME2xNE4zPDV{IN88US=>	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
HCC38	NEfiU5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEXoWWRKSzVyPUGwMlMzOiEQvF2=	NWL2OHhGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
LK-2	MoHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DFXGlEPTB;MUCuOFIxQCEQvF2=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
SF126	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzrTJE5UUN3ME2xNE41PzJ5IN88US=>	NIrxWlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
SK-MEL-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3zWNGlEPTB;MUCuO\|g{QCEQvF2=	NEjJUpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
ACN	NXjMNmdiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvGWpFKSzVyPUGwMlg3PzlizszN	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
BB30-HNC	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTFyLki3NVEh\|ryP	MnPaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
NCI-H747	NELIXmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPjfndoUUN3ME2xNE45PzR4IN88US=>	MlT2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
KYSE-150	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{Swe2lEPTB;MUGuNFM5PyEQvF2=	M{HpT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
D-247MG	NIfiSYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fsRmlEPTB;MUGuNVAxQSEQvF2=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
BxPC-3	MoL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnq4TWM2OD1zMT6zO\|Q4KM7:TR?=	MmD1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
SK-MEL-30	NIfHTmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3K1emlEPTB;MUGuOFA4QSEQvF2=	NG\JTYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
CAS-1	NXfTb3R1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1XDdmlEPTB;MUGuOFExQSEQvF2=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
no-10	NFrpWmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFvubYZKSzVyPUGyMlEzOTdizszN	MmfJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
NCI-H2405	M3HtUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTF{LkKwN\|Yh\|ryP	NGTmUIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
KGN	NWjzVINHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTF{LkK5NFEh\|ryP	M1P6V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
BB49-HNC	M3;ESGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXn0SYRWUUN3ME2xNk4{QTV4IN88US=>	MlPsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
NCI-H1693	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTF{LkW4NVYh\|ryP	NXnIbXJGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
RO82-W-1	Mlf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmKxTWM2OD1zMz6wOlQ6KM7:TR?=	NEL4WWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
CAL-85-1	NYfFUVMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILpTVVKSzVyPUGzMlQ{QTlizszN	M{jqOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
H-EMC-SS	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTF\|LkmxNFQh\|ryP	NWP6XWhFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
SW1783	M{XlPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTF2LkKzPVEh\|ryP	NITGVos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
LB771-HNC	M1XRZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTF2LkSxPUDPxE1?	Mlj6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
HCC70	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXGwdnN4UUN3ME2xOE41OjN\|IN88US=>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
KNS-81-FD	NVr3SGJWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7oTWM2OD1zND63NFQ2KM7:TR?=	MoPKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
KYSE-520	NF;vUZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTF2LkmyO{DPxE1?	NIr4R5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
TGBC24TKB	NWCx[\|R4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnK5TWM2OD1zND65OVM6KM7:TR?=	MkXVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
SNB75	MnfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHv1V\|ZKSzVyPUG1MlA4OjlizszN	NGnoUoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
SW872	M2r5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\mWGlEPTB;MUWuNlIyQCEQvF2=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
U031	Mm\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4i0bmlEPTB;MUWuPFAzQCEQvF2=	NYDWVIRTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
ChaGo-K-1	Mnu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\G[YtPUUN3ME2xOU45OzV7IN88US=>	NELOZoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
NCI-H441	M1TvR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRTF4LkCwN\|kh\|ryP	M1u2dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
TE-12	NHT2UmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVGyU5JzUUN3ME2xOk4yQDd\|IN88US=>	NXfhXmxKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
NCI-H1755	NHnN[XlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTF4LkW3N{DPxE1?	NEPaVms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
KNS-42	M3Hwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUW1XWluUUN3ME2xOk43PTh7IN88US=>	NVPtSIk4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
SK-PN-DW	MnSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1mzb2lEPTB;MUeuOFIxOSEQvF2=	M2XIRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
NCI-H226	M4m2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHYVIRKSzVyPUG3Mlk{PDVizszN	MmXpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
K-562	NGPnV\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;XdXZRUUN3ME2xPE43OzF5IN88US=>	NGLM[Ig9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
A388	Ml\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3izS2lEPTB;MUmuNFMxOyEQvF2=	NWXn[nB5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
ZR-75-30	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTF7LkC5Olgh\|ryP	NILxTlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
LU-135	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUHPWWFsUUN3ME2xPU4zPjN4IN88US=>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
NCI-H2029	M3:zc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MorqTWM2OD1zOT62NFIyKM7:TR?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
HT-1197	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFHzVZpKSzVyPUG5MlkzOjdizszN	NH3SeoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
IGR-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPTTWM2OD1{MD6zNVE4KM7:TR?=	NVX6WXJ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
U-87-MG	NYXOR4tST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY[1bnRbUUN3ME2yNE43PDF\|IN88US=>	M3TmOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
NCI-H1304	NWXpOlNxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYj5[lJsUUN3ME2yNE44PTBzIN88US=>	NFfVe2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
RCC10RGB	Mn3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTJzLkK4Nlkh\|ryP	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
NCI-H520	NF:1cVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjuc2RKSzVyPUKyMlc3OTFizszN	MoT2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
SK-LU-1	NGr0VXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1vqbWlEPTB;MkOuNFcyQCEQvF2=	M2nzdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
UACC-893	NH\kc\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MknDTWM2OD1{Mz6xNFM5KM7:TR?=	NUH5[3FuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
NCI-H2347	MnywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPXZ45KSzVyPUKzMlI3PzRizszN	M{HLNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
U-118-MG	NIS3SFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX23SoFMUUN3ME2yN{44OjF5IN88US=>	M{XWSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
NCI-H596	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlTnTWM2OD1{Mz65NFU2KM7:TR?=	M3zPR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
MZ1-PC	NYL1UGpHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTJ2Lk[3OVkh\|ryP	MmjJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
SW1417	MnPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4O0NGlEPTB;MkWuNlQ6QCEQvF2=	NXHuVVlbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
NCI-H82	NHXwPVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\kcZR3UUN3ME2yOk41Ojh6IN88US=>	M3G0bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
COLO-678	M3TlcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTJ5LkS5NVkh\|ryP	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
KURAMOCHI	NIPKdVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjCdJFKSzVyPUK4MlEzPiEQvF2=	MnnuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
NCI-H1650	MnzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljJTWM2OD1\|MD6xPVI1KM7:TR?=	NGrDR5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
HCC1954	MlTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWf5PYliUUN3ME2zNU4{PjZ4IN88US=>	NUL0eoh2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
GAK	NYXVSnhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXTyUJNIUUN3ME2zNk4zPjF4IN88US=>	NGPkSG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
YAPC	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnlTWM2OD1\|Mz63OlQ5KM7:TR?=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
NCI-H2228	NF:4fo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2rLZmlEPTB;M{SuN\|YxPSEQvF2=	NVjoXFY2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
VMRC-RCZ	NHXwTFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvzTWM2OD1\|Nj6zNFIzKM7:TR?=	NF[2e5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
NMC-G1	MlOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTN5LkC1Nlkh\|ryP	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
D-336MG	NVXtbW5[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUCwPZF7UUN3ME20NU45PDR{IN88US=>	MonKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
UACC-62	NVq2TVczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M17KT2lEPTB;NEKuOVUxPSEQvF2=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
C-33-A	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\VTWM2OD12NT6zNlU3KM7:TR?=	NH23epQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
HCC1937	NUDoXHlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTR5LkG5OVgh\|ryP	NY\GPY9kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
HDLM-2	M1H3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGiwfFJKSzVyPUS3MlIzQDdizszN	M4e1XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
NCI-H727	Ml7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTR5LkK0OVEh\|ryP	M3vNeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
NY	NFTzO2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHX[4JzUUN3ME20PU4{QTB6IN88US=>	Ml;TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
NCI-H2291	M{K3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYPZXlFKUUN3ME20PU45OzBzIN88US=>	Ml;YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Ac-Histone H4 / Ac-Histone H3; PubMed: 21598070 J Neurooncol D54 and U87 glioma cells were treated with lower concentrations (1-3 µM) of vorinostat. The effects on histone acetylation was assessed by immunoblotting. phospho-CDK1; PubMed: 21598070 Changes in level of inhibitory phosphorylation of cdk1 after treatment with vorinostat was determined at 24 and 48 h (using a Tyr-15 residue phospho-specific antibody) along with total cdk1 as loading control. phospho-Cdc25c / Cdc25c; PubMed: 21598070 J Neurooncol Time course of changes in phospho-cdc25c levels after exposure to vorinostat (5 µM). Cyclin B1; PubMed: 21598070 J Neurooncol Cyclin B1 levels were determined in D54 and U87 cells after treatment with various doses of vorinostat at 24 and 48 h. c-Myc / c-Raf / Akt / Cyclin D1 / CDK4; PubMed: 19440035 Cancer Biol Ther Cell lysates from JeKo-1 and Mo2058 cells exposed to vorinostat were immunoblotted for c-Myc, c-Raf, AKT, cyclin D1, CDK4 and acetylated histone H3. The levels of β-actin served as the loading control. p-eIF2α / ATF4 / CHOP ; PubMed: 20072656 Neoplasia Western blot was performed to evaluate activated eIF2α (P-eIF2α), translational up-regulation of ATF4, and CHOP expression in U251 cells after vorinostat exposure. p21; PubMed: 21598070 J Neurooncol To determine the dose response relationship to vorinostat, cells were exposed to various higher concentrations (5–10 µM) of the agent and the levels of p21 determined by immunoblotting.	21598070 19440035 20072656
Immunofluorescence	HDAC1 / CK19; PubMed: 29917299 Cancer Sci Immunocytochemistry to detect the expression of HDAC1 and CK 19 in PDAC cells with/without Vorinostat treatment. HDAC1 and CK19 were stained red and green, respectively. The Hoechst‐stained nuclei appear blue. Scale bar: 100 μm. The CK19 expression in PSN1 and MiaPaCa2 was increased by Vorinostat treatment. Nrf2; PubMed: 20566897 Blood Vorinostat induced translocation of Nrf2 from cytosol to nucleus. U937 cells were treated with 2μM vorinostat for 18 hours and then cytospun. Cells were fixed and labeled for Nrf2 protein (red) and nucleus (blue, 4,6-diamidino-2-phenylindole) as described in “Immunofluorescence and confocal microscopy.” Images were taken by Nikon Eclipse TE2000 confocal microscope with 40×/1.30 numeric aperture oil objective lens. Ctrl indicates control cells without treatment; and Vor, vorinostat. α-SMA; PubMed: 26330748 Mol Vis Representative immunofluorescence images and the quantification graph showing the effect of vorinostat (2.5 µM), TGIF1, and TGIF2 siRNA knockdown on αSMA. Control human corneal fibroblast cultures (-TGFβ) showed no αSMA staining. Cultures treated with TGFβ1 (5 ng/ml) showed a robust αSMA staining. Vorinostat treatment markedly attenuated TGFβ-evoked αSMA staining. The knockdown of TGIF1 (+TGFβ+vorinostat+TGIF1siRNA) and TGIF2 alone (+TGFβ+vorinostat+TGIF2siRNA) or in combination (+TGFβ +vorinostat +TGIF1 +2siRNA) markedly blocked the effect of vorinostat on αSMA. Scale bar=100 μm. Ac-STAT3 / IGF2; PubMed: 27086926 Oncogene Immunofluorescence staining of Ac-STAT3 and IGF2 after vorinostat treatment.	29917299 20566897 26330748 27086926
Growth inhibition assay	Cell apoptosis; PubMed: 19440035 Cancer Biol Ther Cells were treated with indicated concentrations of vorinostat for 48 hours. Following this, the percentage of annexin-V-stained apoptotic cells was determined by flow cytometry. Values represented as bar graphs are the mean of 3 experiments plus or minus the standard error (SE) Cell viability; PubMed: 27086926 Oncogene The effects of vorinostat on the viability of the indicated NSCLC cell lines and their corresponding acquired VoR sublines. Cell viability was determined by the MTT assay (n = 3).	19440035 27086926
ELISA	IGF2; PubMed: 27086926 Oncogene Determination of vorinostat-induced IGF2 production by ELISA (n = 3). The conditioned mediums (CMs) obtained from cells treated with vorinostat (5 μM) for 2 days were used for ELISA. IL-13 / IL-10 / IL-5; PubMed: 18541724 Blood Effect of vorinostat on TH1/TH2 cytokine secretion in HL cell lines. Cells were incubated with medium or vorinostat (5 μM) for 24 hours and supernatants were examined for cytokine levels by ELISA. Each value represents a mean of 3 independent experiments done in triplicate (± SEM). M-CSF; PubMed: 23042302 Carcinogenesis Primary PyMT tumor cells were treated with SAHA (0-1000nM) for varying time points (8–48h), and supernatants were assayed by ELISA for M-CSF secretion. P < 0.05 and P < 0.001 versus control treatment. MMP-9; PubMed: 23042302 Carcinogenesis Primary PyMT tumor cells were treated with SAHA (0-1000nM) for varying time points (8–48h), and supernatants were assayed by ELISA for MMP-9 secretion. P < 0.05 and **P < 0.001 versus control treatment.	27086926 18541724 23042302

In vivo

Administration of Vorinostat (~100 mg/kg/day) significantly inhibits the growth of CWR22 human prostate xenografts in nude mice with tumor reductions of 78%, 97% and 97%, at doses of 25 mg/kg/day, 50 mg/kg/day and 100 mg/kg/day, respectively, compared with control. Vorinostat induces the accumulation of acetylated core histones and prostate-specific antigen mRNA expression in CWR22 cells, resulting in higher levels of serum prostate-specific antigen than predicted from tumor volume alone. ^[2] Oral administration of Vorinostat (0.67g/L) crosses the blood-brain barrier, increases histone acetylation in the brain, and dramatically improves the motor impairment in the R6/2 mice model of Huntington's disease. ^[5]

Protocol

Kinase Assay: ^[1]	- Collapse Immunoprecipitation-HDAC assays: The lysate of Jurkat cells is incubated for 1 hour on ice and cleared by centrifugation at 12,000 g for 10 minutes at 4 °C. Supernatants are precleared with 30 μL of 50% protein G-Sepharose slurry for 1 hour at 4 °C. Beads are pelleted by centrifugation and supernatants are incubated for 1 hour at 4 °C with 10 μg of IgG fraction from anti-HDAC1 or HDAC3 polyclonal antisera (preincubated 2 hours at room temperature with either the homologous or heterologous immunizing peptide). Both antisera are raised in rabbits against the carboxylterminal peptide of HDAC1 and HDAC3 by using synthetic peptides coupled to keyhole limpet hemocyanin. 30 μL of 50% protein G-Sepharose slurry is added for 1 hour at 4 °C. Immune complexes are pelleted by centrifugation and washed three times with 1 mL of lysis buffer. Beads are resuspended in 200 μL of HDAC buffer (20 mM Tris-HCl, pH 8.0/150 mM NaCl/10% glycerol), and the HDAC assay is performed with an ³H-acetylated peptide corresponding to amino acids 1-24 of histone H4. Released [³H]acetic acid is quantified by scintillation counting. For inhibitions studies, the immunoprecipitated complexes are preincubated with the different concentrations of Vorinostat for 30 minutes at 4 °C.
Cell Research: ^[2]	- Collapse Cell lines: LNCaP, PC-3, and TSU-Pr1 Concentrations: Dissolved in DMSO, final concentrations ~7.5 μM Incubation Time: 1, 2, 3 and 4 days Method: Cells are exposed to various concentrations of Vorinostat for 1, 2, 3 and 4 days. Cell viability is assessed by trypan blue dye exclusion. (Only for Reference)
Animal Research: ^[2]	- Collapse Animal Models: Male BALB/c nude (nu/nu) mice implanted with CWR22 tumor cells Dosages: ~100 mg/kg/day Administration: Injection i.p. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	52 mg/mL (196.74 mM)
	Water	Insoluble
	Ethanol	'''''3 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Vorinostat (SAHA) SDF

Molecular Weight	264.3
Formula	C₁₄H₂₀N₂O₃
CAS No.	149647-78-9
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	MK0683, Suberoylanilide hydroxamic acid, Zolinza
Smiles	C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03022565	Withdrawn	Drug: Vorinostat	Uveal Melanoma	University of Miami\|University of Miami Sylvester Comprehensive Cancer Center	January 2020	Early Phase 1
NCT03167437	Recruiting	Drug: Vorinostat\|Drug: Ustekinumab	Crohn''s Disease	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	October 30 2017	Phase 1\|Phase 2
NCT03056495	Recruiting	Drug: N-hydroxy-N''-phenyl-octanediamide (Vorinostat)	Alzheimer Disease	German Center for Neurodegenerative Diseases (DZNE)\|University Hospital Bonn\|University of Göttingen	September 28 2017	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommendation about reconstitution of the compound for in vivo animal study?
Answer:
We recommend the following vehicle for S1047: 2% DMSO, 40% PEG 300, 5% Propylene glycol, 1% Tween 80 at 5 mg/mL.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

CAY10603 ^New

CAY10603 (BML-281) is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

Domatinostat (4SC-202) is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589, NVP-LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.
Entinostat (MS-275)

Entinostat (MS-275, SNDX-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, Depsipeptide, FR 901228, NSC 630176) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). Tubastatin A promotes autophagy and increases apoptosis.
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103, MG0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Mocetinostat (MGCD0103) induces apoptosis and autophagy. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Vorinostat (SAHA)